{"id":77182,"date":"2024-03-19T14:32:17","date_gmt":"2024-03-19T14:32:17","guid":{"rendered":"https:\/\/touchendocrinology.com\/?p=77182"},"modified":"2024-04-30T16:05:37","modified_gmt":"2024-04-30T15:05:37","slug":"the-placental-role-in-gestational-diabetes-mellitus-a-molecular-perspective","status":"publish","type":"post","link":"https:\/\/touchendocrinology.com\/diabetes\/journal-articles\/the-placental-role-in-gestational-diabetes-mellitus-a-molecular-perspective\/","title":{"rendered":"The Placental Role in Gestational Diabetes Mellitus: A Molecular Perspective"},"content":{"rendered":"
\n

Gestational diabetes mellitus (GDM) is generally defined as \u201cany degree of glucose tolerance with onset or first recognition during pregnancy\u201d.1<\/sup><\/span>\u00a0It currently is one of the diseases with the highest morbidity among pregnant women.2<\/sup><\/span>\u00a0Determining its prevalence has been a real challenge for the scientific community due to multiple modifications in the diagnostic criteria established in 1964 by O\u2019Sullivan and Mahan.3<\/sup><\/span>\u00a0Globally, its prevalence ranges from 1% to 14%.2<\/sup><\/span>\u00a0Nevertheless, in a systematic review and meta-analysis\u00a0providing updated estimates of<\/span>\u00a0gestational diabetes in Latin American in 2022, the reported prevalence was 8.5%.4<\/sup><\/span><\/p>\n

GDM is a multifactorial disease in which both genetic and environmental components play a crucial role in its aetiopathogenesis.5<\/sup><\/span>\u00a0It is characterized by the inability to compensate for the physiological insulin resistance (IR) generated by hormonal and inflammatory changes that normally occur during pregnancy.6<\/sup><\/span>\u00a0The hyperglycaemia that occurs in GDM has multiple consequences for both the mother and the foetus, not only during intrauterine life but also during childbirth, the perinatal period and beyond.7,8<\/sup><\/span>\u00a0About 50% of women diagnosed with GDM during pregnancy will develop type 2 diabetes mellitus (T2DM) in the future.9<\/sup><\/span>\u00a0Furthermore, foetuses from mothers with GDM can present with short-term complications, such as macrosomia, shoulder dystocia and neonatal hypoglycaemia. These children also have a greater risk of developing obesity and T2DM in adulthood.6<\/sup><\/span><\/p>\n

Many maternal and foetal complications of GDM have been attributed to abnormal placental development and anatomical and functional alterations.10<\/sup><\/span>\u00a0The placenta is a complex organ that separates the maternal and foetal circulations due to its anatomical configuration. As a result, it is exposed to multiple maternal and foetal substrates. Recent studies also highlight the role of certain regulators that are responsible for placental malfunctioning and GDM development.11,12<\/sup><\/span>\u00a0These studies mention several placental hormones, pro-inflammatory molecules, endothelial cell dysfunction and maternal adipose tissues, as well as the interruption of several molecular pathways, such as nuclear factor kappa-light-chain enhancer of activated B cells (NF-\u03baB), peroxisome proliferator-activated receptors (PPARs), sirtuins, 5\u2019 AMP-activated protein kinase (AMPK), glycogen synthase kinase 3 (GSK-3), inflammasome and endoplasmic reticulum stress.13\u201315<\/sup><\/span><\/p>\n

This review aims to illustrate the role of the placenta in the development of GDM from a molecular perspective. We start by describing the pro-inflammatory factors and changes in different hormones, such as the placental lactogen, PGH and adipokines, which precede the anatomical disturbances leading to alterations in the placental endothelial and angiogenic factors and transporters. Finally, we explore their impact on foetal development.<\/p>\n

From\u00a0physiological\u00a0<\/span>insulin resistance<\/span>\u00a0to\u00a0<\/span>gestational diabetes<\/span>: When equilibrium is lost<\/span><\/h1>\n

Glucose is the primary energy substrate needed for foetal and placental growth. Since foetal gluconeogenesis is minimal during gestation, pregnant women undergo several physiological changes in their metabolic, renal, immune, cardiovascular, haematologic and respiratory systems to guarantee a continuous and adequate supply of glucose to the foetus (Figure 1<\/em><\/span>).16,17<\/sup><\/span>\u00a0Regarding metabolic changes, the onset of physiological IR, which increases as the pregnancy progresses, is necessary to originate a maternal\u2013foetal glucose transfer system via facilitated diffusion, mainly through the glucose transporter 1 (GLUT1).18,19<\/sup><\/span><\/p>\n

\n

Figure 1: <\/span>Physiological changes in macromolecule metabolism during pregnancy16<\/sup><\/span><\/h2>\n

\"\"<\/p>\n<\/div>\n

In a normal pregnancy, there is an increase in insulin sensitivity during the first half of the pregnancy. Subsequently, a decrease in insulin sensitivity of up to 60% has been observed.20<\/sup><\/span>\u00a0This is followed by reversible compensatory changes in pancreatic beta cells, perhaps involving an increase in their number (hyperplasia) and size (hypertrophy) due to higher levels of oestrogen, progesterone, human placental lactogen (hPL), prolactin (PRL), kisspeptin and cortisol, among other growth factors.21<\/sup><\/span><\/p>\n

Both hPL and PRL exert their effects via prolactin receptors (PRLRs), which are specifically expressed in pancreatic beta cells. The intracellular mechanisms of these receptors involve the regulation of pro-proliferative and anti-apoptotic pathways via the Janus kinase 2-signal transducer and activator of transcription 5 (JAK2\/STAT5) pathway, mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), and protein kinase B (AKT).22 <\/sup><\/span>Furthermore, there is an increase in glucokinase synthesis, resulting in a decrease in glucose-induced insulin secretion threshold, leading to hyperinsulinaemia, which allows the maintenance of euglycaemia during pregnancy.19,23<\/sup><\/span>\u00a0Studies show that the increase in hPL-dependent insulin secretion is mediated by increased levels of enzymes regulating serotonin synthesis, such as tryptophan hydroxylase 1 and 2.24<\/sup><\/span>\u00a0Likewise, there is hypertrophy and compensatory hyperplasia of pancreatic beta cells in the mother as a physiological adaptation to hPL pregnancy. When gestation ends, the pancreatic beta-cell mass starts to regress until it reaches normal conditions.25<\/sup><\/span>\u00a0Although the mechanisms responsible for these processes are not yet completely understood, it is known that, after childbirth, the beta-cell mass is reduced via apoptosis.26<\/sup><\/span>\u00a0Other studies suggest that this is due to a reduction in their size and proliferation.27<\/sup><\/span>\u00a0However, these processes are yet to be demonstrated in humans.28<\/sup><\/span><\/p>\n

In women who are obese, pancreatic beta cell dysfunction \u2013 including the inability of beta cells to undergo adaptive changes after the first trimester of pregnancy \u2013 may create a pro-inflammatory environment, which is capable of disrupting the appropriate response before the endocrine signs of pregnancy, increasing the risk of developing GDM.29<\/sup><\/span>\u00a0This phenomenon may be explained by an increase in platelet-derived growth factor\u00a0<\/span>because the levels of this peptide are inversely related to pancreatic beta-cell function in patients with GDM.\u00a0<\/span>On the other hand, it is believed that\u00a0the\u00a0<\/span>chemokine (C-X-C motif) ligand 10<\/span>\u00a0(<\/span>CXCL10), an inflammatory marker, is capable of inhibiting the proliferation of pancreatic beta cells through binding to\u00a0<\/span>C-X-C motif ligand 3\u00a0<\/span>(CXCL3)<\/span>, or through interaction with the toll-like receptor 4 as part of the\u00a0NF-\u03baB<\/span>\u00a0activation pathways mediating IR in GDM.30<\/sup><\/span>\u00a0Although an in-depth review of the immunological alterations in GDM is not within the scope of this work, these findings highlight the immune-related features mediating GDM pathogenesis.<\/p>\n

In pregnant women, several factors increase the risk of a disturbance in physiological IR. These include family and personal history of diabetes mellitus, obesity, race (primarily indigenous people worldwide, African American and Hispanic),23,24<\/sup><\/span>\u00a0and advanced maternal age (\u226535) (Table 1<\/em><\/span>).24,31<\/sup><\/span>\u00a0As a result, IR becomes more severe and cannot be compensated by maternal hyperinsulinemia, resulting in the characteristic hyperglycaemia of GDM.32<\/sup><\/span>\u00a0The mechanism by which these alterations occur requires further study. However, it is believed that obesity causes a decrease in hPL levels via the downregulation of CCAAT-enhancer binding protein transcription factors, which are co-expressed with hPL in the syncytiotrophoblast (SCTB). C\/EBP binds to an enhancer region downstream of the\u00a0hPL<\/em>\u00a0gene, modifying its expression. Therefore, its downregulation results in deficiencies in compensatory metabolic effects.33<\/sup><\/span><\/p>\n

\n

Table 1: <\/span>Risk factors for gestational diabetes mellitus31<\/sup><\/span><\/h2>\n
\n\n\n\n\n\n\n\n\n\n
\n

Low risk<\/b><\/p>\n<\/td>\n

\n

High risk<\/b><\/p>\n<\/td>\n<\/tr>\n<\/thead>\n

\n

Ethnic group with a low incidence of GDM<\/sup><\/p>\n<\/td>\n

\n

Being part of an ethnic group with a high incidence of GDM<\/sup><\/p>\n<\/td>\n<\/tr>\n

\n

No family history of DM<\/sup><\/p>\n<\/td>\n

\n

First-degree family history of DM<\/sup><\/p>\n<\/td>\n<\/tr>\n

\n

Younger than 25 years old<\/p>\n<\/td>\n

\n

Previous detection of glucose intolerance<\/p>\n<\/td>\n<\/tr>\n

\n

Normal weight<\/p>\n<\/td>\n

\n

Obesity<\/p>\n<\/td>\n<\/tr>\n

\n

Normal weight at birth<\/p>\n<\/td>\n

\n

Glycosuria accentuated during pregnancy<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

\n
\n

Adapted from\u00a0Santamaria et al., 2011.<\/span>31<\/sup><\/span><\/span><\/span><\/span><\/em><\/p>\n<\/div>\n

\n

DM<\/span>\u00a0=\u00a0diabetes mellitus<\/span>; <\/span>GDM<\/span>\u00a0=\u00a0gestational diabetes mellitus<\/span>.<\/span><\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n

The incidence of GDM is higher among women with a higher body mass index (BMI) and weight before pregnancy compared with those with a normal BMI. A significant weight gain during the first trimester was positively associated with GDM in women with high BMI before pregnancy.26<\/sup><\/span>\u00a0These alterations are primarily seen in the last trimester. Hence, the diagnosis of GDM is made after week 24 using specific diagnostic criteria (Figure 2<\/span>).31,35,36<\/sup><\/span><\/p>\n

\n

Figure 2: <\/span>Different diagnostic criteria for gestational diabetes mellitus and recommending associations<\/h2>\n

\"\"<\/p>\n

Algorithm formulated from diagnostic measures outlined in international guidelines from Harris, 1995;34<\/sup><\/span>\u00a0Carpenter and Coustan, 1982;35<\/sup><\/span>\u00a0International Association of Diabetes and Pregnancy Study Groups Consensus Panel, 2010.36<\/sup><\/span><\/em><\/p>\n

ACOG =\u00a0American College of Obstetricians and Gynecologists<\/span>;\u00a0<\/span>ADA =\u00a0American Diabetes Association<\/span>;\u00a0<\/span>h = hour;\u00a0<\/span>IADPSG =\u00a0International Association of Diabetes and Pregnancy Study Groups<\/span>;\u00a0<\/span>NGGD =\u00a0National Diabetes Data Group<\/span>;\u00a0<\/span>NIH =\u00a0National Institutes of Health<\/span>;\u00a0<\/span>OGTT =\u00a0oral glucose tolerance test<\/span>;\u00a0<\/span>WHO = World Health Organization.<\/span><\/em><\/p>\n<\/div>\n

Placental\u00a0hormones:\u00a0W<\/span>hen the good goes bad<\/span><\/h1>\n

Placental\u00a0lactogen and\u00a0<\/span>placental growth hormone<\/span><\/h2>\n

Since the mid 20th century, the main placental hormones, hPL and placental growth hormone (PGH), have been considered vital elements in the aetiopathogenesis of GDM, given their known diabetogenic effects in pregnant women.36<\/sup><\/span>\u00a0Nevertheless, even though the current evidence is not conclusive, it suggests a possible secondary role within the pathogenesis of this metabolic disease, with a greater emphasis on PGH dysregulation.37<\/sup><\/span><\/p>\n

PGH is a polypeptide drug synthesized in placental SCTB from gestational weeks 13 to 20, replacing the pituitary growth hormone from that moment onwards.32<\/sup><\/span>\u00a0Its release is independent of the growth hormone-releasing hormone and induced by maternal hypoglycaemia.33<\/sup><\/span>\u00a0The direct and indirect effects of PGH as a primary regulator of insulin growth factor 1 (IGF-1) are limited to maternal and placental tissues, regulating placental growth and blood flow and generating a state of physiological IR to reduce the maternal use of glucose so that it can reach the foetus and allow adequate growth and development.31<\/sup><\/span>\u00a0Nonetheless, insulin is not the only hormone able to activate these signalling pathways since cytokines, as well as other hormones and growth factors, play a very important role in their activation. These molecules are also involved in cellular metabolism and may affect the transport of nutrients.38<\/sup><\/span><\/p>\n

Among the mechanisms by which PGH generates a state of IR is a reduction in adiponectin synthesis. It is an important insulin-sensitizing and anti-inflammatory hormone, possibly via the activation of STAT5 proteins and their posterior binding to adiponectin promoter sites, decreasing its expression and release.36<\/sup><\/span>\u00a0Furthermore, it inhibits the insulin intracellular signalling pathway, with subsequent inhibition of glucose transporter 4 (GLUT4) translocation via the induction of expression of the gene-encoding\u00a0p85<\/em>\u00a0subunits;\u00a0this competitively inhibits insulin receptor substrate 1 (IRS-1), which activates PI3K by preventing its heterodimerization with a p110 subunit in insulin-dependent tissues<\/span>.39,40<\/sup><\/span>\u00a0Thus, along with other diabetogenic hormones, this mechanism creates a diabetogenic environment that favours maternal catabolic processes that generate energetic substrates for the foetus. Although these processes occur physiologically, their role in GDM has been associated with an overproduction of PGH,41 <\/sup><\/span>demonstrating a possible dose\u2013dependent relationship. However, the mechanisms causing these findings have not been completely elucidated.<\/p>\n

Moreover, hPL is a polypeptide hormone synthesized by SCTB, whose levels increase significantly at the start of the second trimester. Its effects are mediated by PRLRs, activation of which mainly regulates the function and proliferation of pancreatic beta cells to maintain insulin release that compensates for the state of IR generated during gestation. Lepercq\u00a0<\/span>et al. proposed that polymorphisms of a single nucleotide (rs10068521 and rs9292578) in the gene encoding for PRLRs are related to a 2.3-fold increased risk of developing GDM.42<\/sup><\/span><\/p>\n

It was proposed that these effects are related to the downregulation of molecules that inhibit the cell cycle, such as the B-cell lymphoma 6 (BCL6<\/span>) protein and cyclin-dependent kinase inhibitor 1 (p21), as well as the induction of anti-apoptotic molecules, such as B-cell lymphoma-extra-large (BCL-xL) and securin (PTTG1), and the protooncogene\u00a0FoxM1<\/em>.43,44<\/sup><\/span>\u00a0Thus, any alterations of these molecules in pancreatic beta cells or PRLRs may be involved in the reduction of proliferation and expansion of pancreatic beta-cell mass, leading to a deficient insulin release incapable of overcoming maternal IR and GDM development.42,45,46<\/sup><\/span><\/p>\n

Leptin<\/h2>\n

Leptin has also been associated with the development of IR and GDM.47<\/sup><\/span>\u00a0This polypeptide hormone is mainly synthesized in white adipose tissues. However, during gestation, the SCTB constitutes the primary synthesizing tissue. Hence, leptin levels are higher than they are in non-pregnant women48<\/sup><\/span>\u00a0. These levels progressively increase after implantation, reaching a peak between weeks 24 and 26, and persist until the immediate postpartum period.49,50<\/sup><\/span>\u00a0During gestation, leptin regulates vital processes, such as implantation, mitogenesis and placental growth, as well as the placental transport of amino acids, the release of human chorionic gonadotropin, immune response and maternal appetite.51,52<\/sup><\/span><\/p>\n

Although a state of hyperleptinaemia is considered physiological, multiple studies reported significantly higher leptin levels in women with GDM.53\u201355<\/sup><\/span>\u00a0This could be the result of a combination of factors, including polymorphisms in the LEP rs2617270 allele of the gene that codes for this hormone, obesity prior to conception and excessive weight increase during pregnancy.52,55\u201357<\/sup><\/span>\u00a0These conditions are associated with IR and states of compensatory hyperinsulinaemia. Since insulin is a critical inductor of leptin secretion by white adipose tissues, it further stimulates its release, causing a vicious cycle. Moreover, despite the fact that leptin released by trophoblastic cells has a wide range of biological functions and plays a role in the successful establishment of pregnancy, it results in a higher hyperleptinaemia under these conditions, contributing to glucose resistance.58<\/sup><\/span><\/p>\n

In this sense, it was proposed that hyperleptinaemia during the first trimester could significantly increase the risk of developing GDM by further accentuating the state of physiological IR via the release of tumour necrosis factor-alpha and interleukin 6 (IL-6) in the placenta.59<\/sup><\/span>\u00a0These inhibit the insulin intracellular signalling pathway and decrease its peripheral effects.60<\/sup><\/span>\u00a0Furthermore, the hyperleptinaemia would increase lipid mobilization, accentuating the lipotoxicity states of peripheral tissues.61<\/sup><\/span><\/p>\n

Resistin<\/h2>\n

Resistin is another adipokine that has generated interest over the last decades due to its association with IR, participating in entities such as T2DM, metabolic syndrome and obesity.62,63<\/sup><\/span>\u00a0This adipokine is a polypeptide hormone composed of 108 amino acids secreted by adipose cells during adipogenesis. Based on recent studies, resistin is also secreted by the pancreatic islets, skeletal muscle, mononuclear cells and liver, as well as the placenta, which is the primary source of resistin during gestation.62,63<\/sup><\/span><\/p>\n

Like the previously described hormones, resistin secretion is progressive, reaching its peak in the third trimester and returning to normality after childbirth.64<\/sup><\/span>\u00a0It was reported that women with GDM have higher serum resistin levels.65 <\/sup><\/span>These levels increase even further if there is obesity since, just as with leptin, supraphysiological insulin levels stimulate resistin release even further in the placenta and adipose tissues.61<\/sup><\/span>\u00a0On the other hand, case-control studies have not shown an association between resistin levels and GDM, suggesting that resistin does not predict risk for this disease.44<\/sup><\/span><\/p>\n

The implication of resistin in GDM development can be explained by its actions on the pancreatic islet, where it induces the expression of the suppressor of cytokine signalling 3 (SOCS3<\/em>) and inhibits the phosphorylation of the AKT pathway, leading to a decrease in insulin release.66<\/sup><\/span>\u00a0Moreover, it reduces the insulin sensitivity of target tissues (skeletal muscle, adipose tissue and liver), affecting the translocation of GLUT4 and disturbing glucogenic metabolism.67<\/sup><\/span>\u00a0In the liver, resistin influences lipid metabolism by decreasing AMPK phosphorylation, which results in a decrease in beta-oxidation and increments in esterified fatty acids and triacylglycerides, leading to lipid accumulation in the liver parenchyma. However, given that the estimation of resistin has not been standardized, its relationship with GDM has not been completely elucidated.68<\/sup><\/span><\/p>\n

Diabetes\u00a0during the third trimeste<\/span>r: From\u00a0subtle to catastrophic placental changes<\/span><\/h1>\n

In GDM, there is a growing dysregulation of glucose metabolism, with the participation of a complex network of signalling molecules that result from a process of low-grade inflammation. When the third trimester is reached, this situation reaches its peak, and hyperglycaemia manifests. This results in micro- and macroscopic alterations in placental anatomy and function.69<\/sup><\/span><\/p>\n

Anatomical\u00a0alterations of the placenta<\/span><\/h2>\n

Macroscopically, at full term, the placenta is circular, with an approximate diameter of 22 cm, thickness of 2.5 cm and an average weight of 470 g.70<\/sup><\/span>\u00a0These characteristics vary from one placenta to another. The placenta has two surfaces: the foetal (chorionic plate) and the maternal side (basal plate or decidua). The latter comprises a mixture of basal decidua and trophoblastic cells and contains placental cotyledons or lobes. Between the chorionic and decidual plate, there is an intervillous space divided by incomplete septa formed by extravillous trophoblast, decidual cells and fibrinoid tissue. Furthermore, there are villi extending from the chorionic plate. These are covered by the placental membrane or barrier, constituted by the cytotrophoblast (CTB) and the SCTB; these can be classified into floating, anchoring or exchange villi, depending on their function.70<\/sup><\/span>\u00a0Floating villi are subdivided according to their stromal characteristics and calibre into mesenchymal villi (rich in mesenchymal cells), immature intermediate villi (with stromal channels containing foetal macrophages or Hofbauer cells), stem villi (the largest ones, with a perivascular contractible system around its main vessels), mature intermediate villi (only contain vessels and capillaries within loose stroma), and terminal villi (possess sinusoids and capillaries with a thin vasculosyncytial membrane).71<\/sup><\/span><\/p>\n

In contrast, women with uncontrolled GDM have bigger placentas. This organ becomes thick and plethoric, which can explain the significant increase in placental weight. Studies reported that the placentas of patients with GDM are heavier compared with those from normoglycaemic controls.72<\/sup><\/span>\u00a0The placentas of pregnant women diagnosed with GDM are 22% heavier and have 33\u201385% bigger diameter and central thickness, respectively, compared with normal placentas.72<\/sup><\/span><\/p>\n

Microscopically, fibrinoid necrosis, vascular lesions, an increase in blood vessels within chorionic villi, oedematous intima, fibrin deposits in SCTB, focal calcifications, Hofbauer cell hyperplasia, syncytial nodes and marked CTB hyperplasia are also attested. It is relevant that the vasculosyncytial membrane of terminal villi has an oedematous stroma, increased syncytial nodes and fibrin deposits. These changes can negatively affect vascular transport, leading to hypoperfusion; this increases the risk of placental infarction, villous immaturity and decidual vasculopathy.72,73<\/sup><\/span><\/p>\n

Trophoblastic proliferation has been described as uncontrolled, with cellular incoordination due to alterations in placental growth factors, such as vascular endothelial growth factor (VEGF) and colony-stimulating factor.74<\/sup><\/span>\u00a0This results from a hypoxic environment emanating from hyperglycaemia due to the activation of pathways, such as the PI3K\/AKT1 pathway.75<\/sup><\/span>\u00a0An increase in capillary surface and blood vessel penetration was also observed in the placentas of women with GDM due to higher oxygen demand, with significantly more villous CTB, fibroblasts and macrophages.76<\/sup><\/span>\u00a0Moreover, a reduction in the apoptotic index was observed in the placentas of pregnant women with GDM, which was associated with an increase in maternal weight.77<\/sup><\/span> Finally, regarding the trophoblastic cell cycle, the metabolic environment of GDM affects the expression of genes that control the cell cycle, such as p27 <\/em>and\u00a0p57.<\/em>\u00a0The latter is a tumour suppressor and an inhibitor of the cell cycle. Its loss leads to a lack of cell cycle control and hyperproliferation. Hence, a lower expression of this gene results in large and heavy placentas in GDM.76<\/sup><\/span><\/p>\n

Placental\u00a0vascular alterations<\/span><\/h2>\n

The vascular integrity of the placenta allows normal foetal development. This situation is altered in women with GDM due to a hyperglycaemic environment, which generates alterations in the macrovasculature (i.e. human umbilical venous and arterial endothelial cell), and the microvasculature of the human placenta (i.e. human placental microvascular endothelial cells) (Figure 3<\/em><\/span>). The hypervascularization resulting from an increase in angiogenesis plays a fundamental role in the development of this disease.78<\/sup><\/span>\u00a0Studies reported that hyperglycaemia, hyperinsulinaemia, dyslipidaemia and hypoxic uterine environment are the causes of VEGF and fibroblast growth factor 2 overexpression.75,79\u201381<\/sup><\/span>\u00a0When VEGF binds to its receptor, it induces the self-phosphorylation of cadherin, which causes interruptions in the adherens junctions of endothelial cells, leading to increased vascular permeability.81,82<\/sup><\/span>\u00a0Although data on angiogenic factors in GDM are limited, there are recent studies suggesting that VEGF overexpression would be secondary to an increase in the angiogenic placental growth factor, which increases cell sensitivity to VEGF.83\u201385<\/sup><\/span><\/p>\n

\n

Figure 3: <\/span>The macrovascular and microvascular alterations of the placenta occur due to maternal hyperglycaemia and compensatory hyperinsulinaemia, which lead to foetal hyperglycaemia<\/h2>\n

\"\"<\/p>\n

Alt = alterations; FGF-2 =\u00a0fibroblast growth factor-2<\/span>; IL = interleukin<\/span>; ROS =\u00a0reactive oxygen species<\/span>; TNF\u03b1 = tumour necrosis factor-alpha; VEGF =\u00a0vascular endothelial growth factor<\/span>.<\/span><\/em><\/p>\n<\/div>\n

Furthermore, L-arginine transport and nitric oxide (NO) synthesis increase due to hyperinsulinaemia.86<\/sup><\/span>\u00a0Insulin binds to the insulin receptor isoform A, triggering the p42\/44 MAPK signalling pathway, which induces cell growth and differentiation, increasing hENT2 transporters (L-arginine transport). Insulin also activates the insulin receptor isoform B, which increases D-glucose metabolism and NO synthesis. In the absence of the disease, both signalling pathways maintain equilibrium in endothelial cells, but NO is also a free radical that has been associated with endothelial dysfunction.86<\/sup><\/span>\u00a0It is suggested that the GDM-related increase in NO production may have a potential role in the early stages of endothelial dysfunction in these patients.87<\/sup><\/span><\/p>\n

Moreover, in normoglycaemic patients, there is a balance between placental mucin 1 (MUC1<\/em>) and adrenomedullin (ADM) in the promotion of placental growth and invasion. ADM is a negative regulator of\u00a0MUC1<\/em>\u00a0gene expression in trophoblastic cells.88<\/sup><\/span> However, due to the hypoxia caused by vascular alterations in the placenta, MUC1<\/em> overexpression has been described.89<\/sup><\/span>\u00a0The role of ADM in early gestation has also been studied, suggesting that it regulates the optimal expression of\u00a0MUC1<\/em>\u00a0to promote implantation and facilitate TB invasion.90<\/sup><\/span><\/p>\n

Alterations in\u00a0placental transport<\/span><\/h2>\n

Foetal development is closely related to the ability to transport nutrients to the foetus via maternal\u2013foetal circulations.59<\/sup><\/span>\u00a0Illnesses such as GDM and obesity cause a positive energy balance, increasing the insulin concentration in the blood and triggering a dysregulation of growth factors, such as IGF-1, increasing the risk of foetal overgrowth.91<\/sup><\/span><\/p>\n

According to a study by Jansson and Powell, the placenta acts as a nutrient sensor.92<\/sup><\/span>\u00a0When the availability of nutrients decreases or is limited, foetal growth slows down or is restricted. On the other hand, there is an increase or acceleration of growth when there is an excess of nutrients. There is also an alternative hypothesis, which suggests that the placenta may respond in a compensatory fashion to the regulations in the activity of transporters upon high or low nutrient levels to maintain normal foetal growth<\/s><\/s>.93<\/sup><\/span><\/p>\n

\n

Figure 4: <\/span>Physiopathology of foetal macrosomia<\/h2>\n

\"\"<\/p>\n

GLUT1 = glucose transporter 1.<\/span><\/em><\/p>\n<\/div>\n

It is known that there is an alteration in placental function in response to maternal obesity. Hence, studies have shown that the capacity of the placenta regarding the transport of amino acids and lipids is greater in women with obesity; likewise, passive permeability of the placenta and glucose transporters are observed to be upregulated in parallel with increased foetal growth.94,95<\/sup><\/span>\u00a0These placental changes are discussed further below.<\/p>\n

Lipids are found in the maternal circulation as fatty acids and triacylglycerides, which cannot penetrate the SCTB. Therefore, they must be hydrolyzed by lipoprotein lipase (LPL). LPL and endothelial lipase (EL) are expressed in microvilli, and their activity is influenced by cytokines, insulin, IGF-1, and leptin.95<\/sup><\/span>\u00a0<\/em>One\u00a0<\/span>in vitro<\/em>\u00a0study showed that high IL-6 levels can cause fatty acid accumulation in trophoblasts\u00a096<\/sup><\/span>\u00a0. Hence, cytokines can regulate lipid metabolism in the placenta.97<\/sup><\/span>\u00a0However, the elevation of these cytokines does not modify the function of fatty acid transporter proteins, adipophilin or the activity of LPL.97<\/sup><\/span><\/p>\n

Furthermore, studies with placental endothelial cells have shown an increased EL expression in the placentas of patients with obesity and GDM, which suggests that low-grade inflammation and other diabetogenic conditions generate a dysregulation of EL during gestation, where leptin and tumour necrosis factor-alpha have a key regulating role.36,98<\/sup><\/span>\u00a0Both cytokines contribute to an increase in the placental regulation of phospholipase A2 family members, leading to the accumulation of omega-3 polyunsaturated fatty acids in placental tissues.45,49<\/sup><\/span>\u00a0In this sense, omega-3 polyunsaturated fatty acids are widely known for their benefits in maternal and foetal regulation of metabolism, inflammation, oxidative stress and disorders such as foetal macrosomia and preeclampsia; in patients with GDM, these processes are highly compromised, which interrupts normal transport, resulting in reduced foetal levels, contributing negatively to all the aforementioned factors.99<\/sup><\/span><\/p>\n

Moreover, the transport of amino acids is also altered in GDM. It was proven that there is an increase in the transport and concentrations of essential and non-essential amino acids.100<\/sup><\/span>\u00a0The most studied amino acid transport systems are system A and system L.100<\/sup><\/span>\u00a0Alanine, glycine and serine\u00a0are transported by amino acid transport system A,<\/span>\u00a0which is highly stimulated by insulin, leptin, IGF-1, and IL-6 and are present in the SCTB (especially in microvilli). On the other hand, amino acids with high molecular weights, such as leucine, are transported by amino acid transport system L, which is highly stimulated by glucose and insulin, and is found in microvilli and on the basal membrane.95<\/sup><\/span><\/p>\n

Lastly, glucose is one of the primary energy substrates for foetal and placental growth. Since glucose production in the foetus is minimal, the foetus is dependent on maternal glucose. According to a study on placental perfusion, there are no differences in the flow of glucose that enters the foetus through a concentration gradient from the placenta, independently of a GDM diagnosis.101<\/sup><\/span>\u00a0Furthermore, evidence supports the notion that the placenta is not related to the transference of maternal glucose to the foetus in GDM, and the concentration gradient is the critical point in this pathology.101,102<\/sup><\/span>\u00a0Nevertheless, an increase in placental size increases glucose transport, contributing to the accumulation of foetal fat in GDM.59<\/sup><\/span>\u00a0GDM and obesity are associated with high levels of pro-inflammatory cytokines, which could alter the expression of genes involved in lipid pathways and contribute to the increase in placental lipid transport.103<\/sup><\/span><\/p>\n

The effect of\u00a0placental changes on foetal anthropometric measurements<\/span><\/h1>\n

The alterations in an intrauterine environment that arise from the previously described metabolic and inflammatory disorders generate a series of foetal complications. The most important are foetal macrosomia and decreased muscle mass.<\/p>\n

Foetal\u00a0m<\/span>acrosomia<\/h2>\n

Foetal macrosomia is one of the most common complications of GDM, affecting approximately 15\u201345% of infants born to patients with this disease.104<\/sup><\/span>\u00a0Foetal growth is a complex process involving genetic, endocrine and metabolic factors. Therefore, any alterations in one of these factors in the mother, placenta, or foetus can alter foetal growth or result in foetal macrosomia. This condition is defined as a birth weight of 4,000 g or higher. It can be symmetrical or asymmetrical, with the latter being evidence of a diabetic pregnancy. It is characterized by an increase in the abdominal diameter and scapular area of the foetus, in contrast with the dimensions of the head and femur.105<\/sup><\/span><\/p>\n

Although its underlying mechanisms are not entirely understood, foetal macrosomia can be explained by the Pedersen hypothesis, where maternal hyperglycaemia leads to foetal hyperinsulinaemia and an increase in the adipose tissue (Figure 4<\/em><\/span>). When maternal hyperglycaemia is present, glucose crosses the placenta in higher amounts and is stored as glycogen. However, once these glycogen deposits become saturated, the excess glucose and the corresponding foetal hyperinsulinaemia, along with the increase in growth factors similar to insulin, lead to an increase in fat and protein deposits, resulting in macrosomia.106,107<\/sup><\/span><\/p>\n

Foetal macrosomia is also induced by a placental increase in certain genes in mothers without GDM, such as placental expression of\u00a0PPAR alpha and gamma<\/em>, which are considered transcriptional regulators with key functions in lipid metabolism and\u00a0miR-27b<\/em>.108<\/sup><\/span>\u00a0On the other hand, the effects of long non-coding RNAs (lncRNA) in non-diabetic foetal macrosomia have also been studied, suggesting that the lncRNA\u00a0USP2-AS1<\/em>\u00a0promotes placental development by affecting the proliferative activity of placental cells.109<\/sup><\/span>\u00a0Moreover, another study indicated that lncRNA-SNX17 overexpression reduces the expression of\u00a0miR-517a<\/em>, which could play an important role in the regulation of birth weight, and increases the expression of IGF-1 in the human trophoblast cell line HTR- 8\/SVneo, thus enhancing the proliferation of HTR-8\/SVneo.110<\/sup><\/span>\u00a0It also reported that\u00a0lncRNA-SNX17<\/em>\u00a0could promote trophoblast proliferation through the miR-517a\/IGF-1 pathway and could play a role in diabetic macrosomia placentation.110<\/sup><\/span>\u00a0However, further studies are required to elucidate the underlying mechanisms.<\/p>\n

Infants born to women with GDM are susceptible to abnormal foetal growth, even those with normal glucose levels.111<\/sup><\/span>\u00a0This may be explained by the role of foetal IGF-1, which regulates foetal growth and is increased by about 55% during gestation in women with GDM. It is believed that IGF-1 stimulates macrosomia via\u00a0mammalian target of rapamycin<\/span>\u00a0(mTOR) activation and the subsequent increase in essential and non-essential amino acid transporters in the placenta of women with GDM.112<\/sup><\/span><\/p>\n

The overgrowth pattern typically seen in macrosomic newborns is known to be one of asymmetrical growth, with central deposition of subcutaneous fat around the abdomen and back, greater shoulder circumference and increased skin folds.113,114<\/sup><\/span>\u00a0However, no studies have been conducted to confirm the shape of fat mass distribution in macrosomic newborns.115<\/sup><\/span>\u00a0Anthropometric indices have also been established for the early diagnosis of foetal macrosomia, among which the maternal Body Roundness Index, Body Shape Index and Visceral Adiposity Index stand out. In a study conducted by Ozler et al., the efficacy of these anthropometric indices in obese and non-obese pregnant women was investigated; the results found that these were significantly higher in the group of women who were obese who subsequently had a macrosomic newborn.116<\/sup><\/span><\/p>\n

Muscle\u00a0m<\/span>ass<\/h2>\n

Due to an altered cytokine release, low-grade inflammation can lead to changes in foetal muscle development (Figure 5<\/em><\/span>). Inflammation promotes adipogenesis and activates NF-\u03baB to differentiate adipocytes and decrease myogenesis.117<\/sup><\/span>\u00a0Furthermore, the differentiation of mesenchymal cells in muscle tissues is diminished due to the dimerization of\u00a0c-Jun<\/em>\u00a0with the JDP2 protein, which inhibits the transcriptional activity of Jun, inhibiting myogenesis. Thus, a low-grade inflammation decreases myogenesis and increases adipogenesis in foetal skeletal muscle, decreasing its oxidative capacity. Hence, the newborn is at greater risk of having IR, obesity and T2DM in the long term.118<\/sup><\/span><\/p>\n

\n

Figure 5: <\/span>Decrease in the oxidative capacity of skeletal muscle<\/h2>\n

\"\"<\/p>\n

C-Jun =\u00a0transcription factor Jun<\/span>; JDP2 =\u00a0Jun dimerization protein<\/span>\u00a02;\u00a0NF-\u03baB<\/span>\u00a0=\u00a0nuclear factor kappa-light-chain enhancer of activated B cells<\/span>; T2DM = type 2 diabetes mellitus.<\/em><\/p>\n<\/div>\n

It has been postulated that the overexpression of PGH increases the expression of\u00a0p85<\/em>\u00a0subunit proteins of PI3K in insulin-sensitive tissues (i.e. the skeletal muscle).119<\/sup><\/span>\u00a0This decreases its signalling and leads to IR. Furthermore, the IR induced by PGH results in reduced GLUT4 expression and decreased glucose uptake, which would lead to muscle mass loss.120<\/sup><\/span><\/p>\n

The hormonal disturbances and alterations in the placental transport and growth occurring in GDM and described above are summarized in\u00a0<\/em>Table 2<\/em><\/span>.<\/p>\n

\n

Table 2: <\/span>Hormonal disturbances and alterations in placental transport and growth occurring in gestational diabetes mellitus and the impact on the foetus<\/h2>\n
\n\n\n\n\n\n\n\n
\n

Feature<\/b><\/p>\n<\/td>\n

\n

Women without GDM<\/b><\/p>\n<\/td>\n

\n

Proposed pathophysiological effects on the foetus<\/b><\/p>\n<\/td>\n<\/tr>\n<\/thead>\n

\n

Hormones<\/p>\n<\/td>\n

\n

Elevated insulin (insulin resistance)<\/p>\n

Impaired glucose tolerance<\/p>\n

Elevated adipokines<\/p>\n<\/td>\n

\n

Foetal overgrowth (increased risk of macrosomia)<\/p>\n

Risk of foetal hypoglycaemia due to increased insulin secretion<\/p>\n<\/td>\n<\/tr>\n

\n

Placental growth<\/p>\n<\/td>\n

\n

Abnormalities in placental growth and vascular development<\/p>\n

Reduced placental perfusion<\/p>\n<\/td>\n

\n

Foetal hypoxia<\/p>\n

Foetal growth restriction contributing to IUGR<\/p>\n<\/td>\n<\/tr>\n

\n

Placental transport<\/p>\n<\/td>\n

\n

Altered nutrient and oxygen transfer<\/p>\n<\/td>\n

\n

Foetal developmental delay<\/p>\n

IUGR<\/p>\n

Increased risk of metabolic abnormalities<\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n

\n
\n

GDM = gestational diabetes mellitus;\u00a0<\/span>IUGR = intrauterine growth restriction.<\/span><\/em><\/p>\n<\/div>\n<\/div>\n<\/div>\n

Conclusion<\/h1>\n

GDM is characterized by the inability to compensate for the physiological IR of pregnancy. Many factors have been associated with the development of IR during gestation. Placental hormones, along with the increase in the production of pro-inflammatory cytokines, maintain the characteristic low-grade inflammatory state of GDM, which is the cause of morphological and functional changes in the placenta. The placenta plays a crucial role in GDM by functioning as a regulator of maternal and foetal circulations. Hence, changes in its size, vascular lesions and microscopic necrosis would affect this regulation. These changes result in several foetal complications, including foetal macrosomia. This condition originates from alterations in placental transport and a decrease in muscle mass, which results from a constant inflammatory process that decreases myogenesis and increases certain lactogenic hormones. Since the mechanisms by which these hormones interact in this pathology have not been fully elucidated, more research should be done to improve the quality of life of patients with GDM and their future children.<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Gestational diabetes mellitus (GDM) is generally defined as \u201cany degree of glucose tolerance with onset or first recognition during pregnancy\u201d.1\u00a0It currently is one of the diseases with the highest morbidity among pregnant women.2\u00a0Determining its prevalence has been a real challenge for the scientific community due to multiple modifications in the diagnostic criteria established in 1964 […]<\/p>\n","protected":false},"author":142327,"featured_media":31137,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","rank_math_lock_modified_date":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-77182","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-uncategorized","vocabulary_1-diabetes","journal-touchreviews-in-endocrinology"],"acf":{"wpcf-article_introduction":"","wpcf-article_abstract":"During pregnancy, women undergo several metabolic changes to guarantee an adequate supply of glucose to the foetus. These metabolic modifications develop what is known as physiological insulin resistance. When this process is altered, however, gestational diabetes mellitus (GDM) occurs. GDM is a multifactorial disease, and genetic and environmental factors play a crucial role in its aetiopathogenesis. GDM has been linked to both macroscopic and molecular alterations in placental tissues that affect placental physiology. This review summarizes the role of the placenta in the development of GDM from a molecular perspective, including hormonal and pro-inflammatory changes. Inflammation and hormonal imbalance, the characteristics dominating the GDM microenvironment, are responsible for placental changes in size and vascularity, leading to dysregulation in maternal and foetal circulations and to complications in the newborn. In conclusion, since the hormonal mechanisms operating in GDM have not been fully elucidated, more research should be done to improve the quality of life of patients with GDM and their future children.","wpcf-article_keywords":"Foetus<\/span>,\u00a0gestational diabetes<\/span>,\u00a0insulin resistance<\/span>,\u00a0low-grade inflammation<\/span>,\u00a0obesity<\/span>,\u00a0placenta<\/span>,\u00a0quality of life<\/span>","wpcf-article_citation_override":"touchREVIEWS in Endocrinology.<\/em> 2024;20(1):10\u201318","wpcf-compliance-with-ethics":"

\r\n
\r\n
\r\n

This article involves a review of the literature and did not involve any studies with human or animal subjects performed by any of the authors.<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n

<\/div>","wpcf-article_disclosure":"
\r\n
\r\n
\r\n

Valmore Berm\u00fadez, Mar\u00eda Jos\u00e9 Calvo, Heliana Parra, Raquel Santeliz, Jordan Bautista, Eliana Luzardo, Nelson Villasmil, Mar\u00eda Sof\u00eda Mart\u00ednez, Maricamen Chac\u00edn, Cl\u00edmaco Cano, Ana Checa-Ros and Luis D'Marco have no financial or non-financial relationships or activities to declare in relation to this article.<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>","wpcf-review_process":"

\r\n
\r\n
\r\n

Double-blind peer review.<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n

<\/div>","wpcf-authorship":"The named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this manuscript, take responsibility for the integrity of the work as a whole, and have given final approval for the version to be published.","wpcf-article_correspondence":"

Valmore<\/span>\u00a0Berm\u00fadez<\/span><\/span>,\u00a0Facultad de Ciencias de la Salud, Barranquilla, Universidad Sim\u00f3n Bol\u00edvar<\/span>,\u00a0Barranquilla 080002, <\/span>Colombia<\/span><\/span>; valmore.bermudez@unisimon.edu.co<\/span><\/p>\r\n\r\n

\r\n
<\/div>\r\n<\/div>","wpcf-article_support":"
\r\n
\r\n
\r\n

Valmore Berm\u00fadez was supported by the research grant no. CC-0437-10-21-09-10 from Consejo de Desarrollo Cient\u00edfico, Human\u00edstico y Tecnol\u00f3gico (CONDES), University of Zulia, and research grant no. FZ-0058-2007 from Fundacite-Zulia. Juan Bautista De Sanctis was funded by a grant from the Ministry of Education, Youth and Sport, Czech Republic: Molecular and Cellular Clinical Approach to Healthy Ageing, ENOCH (European Regional Development Fund Project No. CZ.02.1.01\/0.0\/0.0\/16_019\/0000868, IMTM #869\/V19).<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>","wpcf-open_access":"

\r\n
\r\n
\r\n

This article is freely accessible at touchENDOCRINOLOGY.com. \u00a9 Touch Medical Media 2024.<\/p>\r\n\r\n<\/div>\r\n<\/div>\r\n<\/div>\r\n

<\/div>","wpcf-article_pdf":"https:\/\/touchendocrinology.com\/wp-content\/uploads\/sites\/5\/2024\/03\/5.-touchENDOCRINOLOGY_20.1_DMarco_10-18.pdf","wpcf-article_pdf-gated":true,"wpcf-article_doi":"https:\/\/doi.org\/10.17925\/EE.2024.20.1.5<\/a>","wpcf-old_nid":"","wpcf-article_image":"","wpcf-editor_choice":false,"wpcf-old_author_ids":"","wpcf-article_references":"

1.<\/span>\u00a0Metzger<\/span>\u00a0BE<\/span><\/span>,\u00a0Coustan<\/span>\u00a0DR<\/span><\/span>.\u00a0Summary and recommendations of the fourth International Workshop-Conference on Gestational Diabetes Mellitus. The organizing committee<\/span>.\u00a0Diabetes Care<\/em><\/span>.\u00a01998<\/span>;21(Suppl. 2)<\/span>:B161<\/span>\u20137<\/span>.<\/p>\r\n

2.<\/span>\u00a0Sonne<\/span>\u00a0DP<\/span><\/span>,\u00a0Hemmingsen<\/span>\u00a0B<\/span><\/span>.\u00a0Comment on American Diabetes Association.\u00a0Standards of Medical Care in Diabetes\u20142017<\/em>. Diabetes Care 2017;40(Suppl. 1):S1\u2013S135<\/span>.\u00a0Diabetes Care<\/em><\/span>.\u00a02017<\/span>;40<\/span>:e92<\/span>\u20133<\/span>.\u00a0DOI<\/span>:\u00a010.2337\/dc17-0299<\/span>.<\/p>\r\n

3.<\/span>\u00a0O\u2019Sullivan<\/span>JB<\/span><\/span>,\u00a0Mahan<\/span>CM<\/span><\/span>.\u00a0Criteria for the oral glucose tolerance test in pregnancy<\/span>.\u00a0Diabetes<\/em><\/span>.\u00a01964<\/span>;13<\/span>:278<\/span>\u201385<\/span>.<\/p>\r\n

4.<\/span>\u00a0Blanco<\/span>\u00a0E<\/span><\/span>,\u00a0Marin<\/span>\u00a0M<\/span><\/span>,\u00a0Nu\u00f1ez<\/span>\u00a0L<\/span><\/span>,\u00a0et al<\/span>.\u00a0Adverse pregnancy and perinatal outcomes in Latin America and the Caribbean: Systematic review and meta-analysis<\/span>.\u00a0Rev Panam Salud Publica<\/em><\/span>.\u00a02022<\/span>;46<\/span>:e21<\/span>.\u00a0DOI<\/span>:\u00a010.26633\/RPSP.2022.21<\/span>.<\/p>\r\n

5.<\/span>\u00a0Hoffman<\/span>\u00a0DJ<\/span><\/span>,\u00a0Powell<\/span>\u00a0TL<\/span><\/span>,\u00a0Barrett<\/span>\u00a0ES<\/span><\/span>,\u00a0Hardy<\/span>\u00a0DB<\/span><\/span>.\u00a0Developmental origins of metabolic diseases<\/span>.\u00a0Physiol Rev<\/em><\/span>.\u00a02021<\/span>;101<\/span>:739<\/span>\u201395<\/span>.\u00a0DOI<\/span>:\u00a010.1152\/physrev.00002.2020<\/span>.<\/p>\r\n

6.<\/span>\u00a0Baz<\/span>\u00a0B<\/span><\/span>,\u00a0Riveline<\/span>\u00a0J-P<\/span><\/span>,\u00a0Gautier<\/span>\u00a0J-F<\/span><\/span>.\u00a0Endocrinology of pregnancy: Gestational diabetes mellitus: Definition, aetiological and clinical aspects<\/span>.\u00a0Eur J Endocrinol<\/em><\/span>.\u00a02016<\/span>;174<\/span>:R43<\/span>\u201351<\/span>.\u00a0DOI<\/span>:\u00a010.1530\/EJE-15-0378<\/span>.<\/p>\r\n

7.<\/span>\u00a0Febres Balestrini<\/span>\u00a0F<\/span><\/span>,\u00a0Zimmer<\/span>\u00a0E<\/span><\/span>,\u00a0Guerra<\/span>\u00a0C<\/span><\/span>,\u00a0et al<\/span>.\u00a0Nuevos conceptos en diabetes mellitus gestacional: Evaluaci\u00f3n prospectiva de 3 070 mujeres embarazadas<\/span>.\u00a0Rev Obstet Ginecol Venez<\/span>.\u00a02000<\/span>;60<\/span>:229<\/span>\u201336<\/span>.<\/p>\r\n

8.<\/span>\u00a0Quintanilla Rodriguez<\/span>\u00a0BS<\/span><\/span>,\u00a0Mahdy<\/span>\u00a0H<\/span><\/span>.\u00a0Gestational Diabetes<\/em><\/span>.\u00a0Treasure Island (FL)<\/span>:\u00a0StatPearls<\/span>,\u00a02023<\/span>.<\/p>\r\n

9.<\/span>\u00a0O\u2019Sullivan<\/span>\u00a0JB<\/span><\/span>.\u00a0Diabetes mellitus after GDM<\/span>.\u00a0Diabetes<\/em><\/span>.\u00a01991<\/span>;40(Suppl. 2)<\/span>:131<\/span>\u20135<\/span>.\u00a0DOI<\/span>:\u00a010.2337\/diab.40.2.S131<\/span>.<\/p>\r\n

10.<\/span>\u00a0Gauster<\/span>\u00a0M<\/span><\/span>,\u00a0Desoye<\/span>\u00a0G<\/span><\/span>,\u00a0T\u00f6tsch<\/span>\u00a0M<\/span><\/span>,\u00a0Hiden<\/span>\u00a0U<\/span><\/span>.\u00a0The placenta and gestational diabetes mellitus<\/span>.\u00a0Curr Diab Rep<\/em><\/span>.\u00a02012<\/span>;12<\/span>:16<\/span>\u201323<\/span>.\u00a0DOI<\/span>:\u00a010.1007\/s11892-011-0244-5<\/span>.<\/p>\r\n

11.<\/span>\u00a0Al-Ofi<\/span>\u00a0E<\/span><\/span>,\u00a0Alrafiah<\/span>\u00a0A<\/span><\/span>,\u00a0Maidi<\/span>\u00a0S<\/span><\/span>,\u00a0et al<\/span>.\u00a0Altered expression of angiogenic biomarkers in pregnancy associated with gestational diabetes<\/span>.\u00a0Int J Gen Med<\/em><\/span>.\u00a02021<\/span>;14<\/span>:3367<\/span>\u201375<\/span>.\u00a0DOI<\/span>:\u00a010.2147\/IJGM.S316670<\/span>.<\/p>\r\n

12.<\/span>\u00a0Bedell<\/span>\u00a0S<\/span><\/span>,\u00a0Hutson<\/span>\u00a0J<\/span><\/span>,\u00a0de Vrijer<\/span>\u00a0B<\/span><\/span>,\u00a0Eastabrook<\/span>\u00a0G<\/span><\/span>.\u00a0Effects of maternal obesity and gestational diabetes mellitus on the placenta: Current knowledge and targets for therapeutic interventions<\/span>.\u00a0Curr Vasc Pharmacol<\/em><\/span>.\u00a02021<\/span>;19<\/span>:176<\/span>\u201392. <\/span>DOI<\/span>:\u00a010.2174\/1570161118666200616144512<\/span>.<\/p>\r\n

13.<\/span>\u00a0Alur<\/span>\u00a0V<\/span><\/span>,\u00a0Raju<\/span>\u00a0V<\/span><\/span>,\u00a0Vastrad<\/span>\u00a0B<\/span><\/span>,\u00a0et al<\/span>.\u00a0Integrated bioinformatics analysis reveals novel key biomarkers and potential candidate small molecule drugs in gestational diabetes mellitus<\/span>.\u00a0Biosci Rep. <\/em><\/span>2021<\/span>;41<\/span>:BSR20210617. <\/span>DOI<\/span>:\u00a010.1042\/BSR20210617<\/span>.<\/p>\r\n

14.<\/span>\u00a0Yang<\/span>\u00a0Y<\/span><\/span>,\u00a0Guo<\/span>\u00a0F<\/span><\/span>,\u00a0Peng<\/span>\u00a0Y<\/span><\/span>,\u00a0et al<\/span>.\u00a0Transcriptomic profiling of human placenta in gestational diabetes mellitus at the single-cell level<\/span>.\u00a0Front Endocrinol (Lausanne)<\/em><\/span>.\u00a02021<\/span>;12<\/span>:679582<\/span>.\u00a0DOI<\/span>:\u00a010.3389\/fendo.2021.679582<\/span>.<\/p>\r\n

15.<\/span>\u00a0de Gennaro<\/span>\u00a0G<\/span><\/span>,\u00a0Palla<\/span>\u00a0G<\/span><\/span>,\u00a0Battini<\/span>\u00a0L<\/span><\/span>,\u00a0et al<\/span>.\u00a0The role of adipokines in the pathogenesis of gestational diabetes mellitus<\/span>.\u00a0Gynecol Endocrinol<\/em><\/span>.\u00a02019<\/span>;35<\/span>:737<\/span>\u201351<\/span>.\u00a0DOI<\/span>:\u00a010.1080\/09513590.2019.1597346<\/span>.<\/p>\r\n

16.<\/span>\u00a0Tan<\/span>\u00a0EK<\/span><\/span>,\u00a0Tan<\/span>\u00a0EL<\/span><\/span>.\u00a0Alterations in physiology and anatomy during pregnancy<\/span>.\u00a0Best Pract Res Clin Obstet Gynaecol. <\/em><\/span>2013<\/span>;27<\/span>:791<\/span>\u2013802. <\/span>DOI<\/span>:\u00a010.1016\/j.bpobgyn.2013.08.001<\/span>.<\/p>\r\n

17.<\/span>\u00a0King<\/span>\u00a0JC<\/span><\/span>.\u00a0Physiology of pregnancy and nutrient metabolism<\/span>.\u00a0Am J Clin Nutr<\/em><\/span>.\u00a02000<\/span>;71(Suppl. 5)<\/span>:1218S<\/span>\u201325S. <\/span>DOI<\/span>:\u00a010.1093\/ajcn\/71.5.1218s<\/span>.<\/p>\r\n

18.<\/span>\u00a0Catalano<\/span>\u00a0PM<\/span><\/span>,\u00a0Tyzbir<\/span>\u00a0ED<\/span><\/span>,\u00a0Wolfe<\/span>\u00a0RR<\/span><\/span>,\u00a0et al<\/span>.\u00a0Longitudinal changes in basal hepatic glucose production and suppression during insulin infusion in normal pregnant women<\/span>.\u00a0Am J Obstet Gynecol<\/em><\/span>.\u00a01992<\/span>;167<\/span>:913<\/span>\u20139<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/s0002-9378(12)80011-1<\/span>.<\/p>\r\n

19.<\/span>\u00a0Michelsen<\/span>\u00a0TM<\/span><\/span>,\u00a0Holme<\/span>\u00a0AM<\/span><\/span>,\u00a0Holm<\/span>\u00a0MB<\/span><\/span>,\u00a0et al<\/span>.\u00a0Uteroplacental glucose uptake and fetal glucose consumption: A quantitative study in human pregnancies<\/span>.\u00a0J Clin Endocrinol Metab<\/em><\/span>.\u00a02019<\/span>;104<\/span>:873<\/span>\u201382<\/span>.\u00a0DOI<\/span>:\u00a010.1210\/jc.2018-01154<\/span>.<\/p>\r\n

20.<\/span>\u00a0Powe<\/span>\u00a0CE<\/span><\/span>,\u00a0Huston Presley<\/span>\u00a0LP<\/span><\/span>,\u00a0Locascio<\/span>\u00a0JJ<\/span><\/span>,\u00a0Catalano<\/span>\u00a0PM<\/span><\/span>.\u00a0Augmented insulin secretory response in early pregnancy<\/span>.\u00a0Diabetologia<\/em><\/span>.\u00a02019<\/span>;62<\/span>:1445<\/span>\u201352<\/span>.\u00a0DOI<\/span>:\u00a010.1007\/s00125-019-4881-6<\/span>.<\/p>\r\n

21.<\/span>\u00a0Sweeting<\/span>\u00a0A<\/span><\/span>,\u00a0Wong<\/span>\u00a0J<\/span><\/span>,\u00a0Murphy<\/span>\u00a0HR<\/span><\/span>,\u00a0Ross<\/span>\u00a0GP<\/span><\/span>.\u00a0A clinical update on gestational diabetes mellitus<\/span>.\u00a0Endocr Rev. <\/em><\/span>2022<\/span>;43<\/span>:763<\/span>\u201393. <\/span>DOI<\/span>:\u00a010.1210\/endrev\/bnac003<\/span>.<\/p>\r\n

22.<\/span>\u00a0Banerjee<\/span>\u00a0RR<\/span><\/span>.\u00a0Piecing together the puzzle of pancreatic islet adaptation in pregnancy<\/span>.\u00a0Ann N Y Acad Sci. <\/em><\/span>2018<\/span>;1411<\/span>:120<\/span>\u201339. <\/span>DOI<\/span>:\u00a010.1111\/nyas.13552<\/span>.<\/p>\r\n

23.<\/span>\u00a0Simpson<\/span>\u00a0S<\/span><\/span>,\u00a0Smith<\/span>\u00a0L<\/span><\/span>,\u00a0Bowe<\/span>\u00a0J<\/span><\/span>.\u00a0Placental peptides regulating islet adaptation to pregnancy: Clinical potential in gestational diabetes mellitus<\/span>.\u00a0Curr Opin Pharmacol<\/em><\/span>.\u00a02018<\/span>;43<\/span>:59<\/span>\u201365<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.coph.2018.08.004<\/span>.<\/p>\r\n

24.<\/span>\u00a0Hill<\/span>\u00a0DJ<\/span><\/span>.\u00a0Placental control of metabolic adaptations in the mother for an optimal pregnancy outcome. What goes wrong in gestational diabetes?<\/span>\u00a0Placenta<\/em><\/span>.\u00a02018<\/span>;69<\/span>:162<\/span>\u20138<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.placenta.2018.01.002<\/span>.<\/p>\r\n

25.<\/span>\u00a0Moyce<\/span>\u00a0BL<\/span><\/span>,\u00a0Dolinsky<\/span>\u00a0VW<\/span><\/span>.\u00a0Maternal \u03b2-cell adaptations in pregnancy and placental signalling: Implications for gestational diabetes<\/span>.\u00a0Int J Mol Sci<\/em><\/span>.\u00a02018<\/span>;19<\/span>:3467<\/span>.\u00a0DOI<\/span>:\u00a010.3390\/ijms19113467<\/span>.<\/p>\r\n

26.<\/span>\u00a0Al-Habib<\/span>\u00a0MF<\/span><\/span>,\u00a0Abdulameer<\/span>\u00a0HH<\/span><\/span>,\u00a0Abood<\/span>\u00a0AH<\/span><\/span>.\u00a0Morphological study of the mice's islets of Langerhans and \u03b2-cells mass assessment during pregnancy and lactation conditions<\/span>.\u00a0Kerbala Journal of Medicine<\/em><\/span>.\u00a02016<\/span>;9<\/span>:2523<\/span>\u201333<\/span>.<\/p>\r\n

27.<\/span>\u00a0Salazar\u2010Petres<\/span>\u00a0ER<\/span><\/span>,\u00a0Sferruzzi\u2010Perri<\/span>\u00a0AN<\/span><\/span>.\u00a0Pregnancy\u2010induced changes in \u03b2\u2010cell function: What are the key players?<\/span>\u00a0J Physiol<\/em><\/span>.\u00a02022<\/span>;600<\/span>:1089<\/span>\u2013117<\/span>.\u00a0DOI<\/span>:\u00a010.1113\/JP281082<\/span>.<\/p>\r\n

28.<\/span>\u00a0Takahashi<\/span>\u00a0M<\/span><\/span>,\u00a0Miyatsuka<\/span>\u00a0T<\/span><\/span>,\u00a0Suzuki<\/span>\u00a0L<\/span><\/span>,\u00a0et al<\/span>.\u00a0Biphasic changes in \u03b2-cell mass around parturition are accompanied by increased serotonin production<\/span>.\u00a0Sci Rep<\/em><\/span>.\u00a02020<\/span>;10<\/span>:4962<\/span>.\u00a0DOI<\/span>:\u00a010.1038\/s41598-020-61850-1<\/span>.<\/p>\r\n

29.<\/span>\u00a0Shan<\/span>\u00a0Z<\/span><\/span>,\u00a0Xu<\/span>\u00a0C<\/span><\/span>,\u00a0Wang<\/span>\u00a0W<\/span><\/span>,\u00a0Li<\/span>\u00a0W<\/span><\/span>.\u00a0Enhanced PDGF signaling in gestational diabetes mellitus is involved in pancreatic \u03b2-cell dysfunction<\/span>.\u00a0Biochem Biophys Res Commun<\/em><\/span>.\u00a02019<\/span>;516<\/span>:402<\/span>\u20137<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.bbrc.2019.06.048<\/span>.<\/p>\r\n

30.<\/span>\u00a0Abu Samra<\/span>\u00a0N<\/span><\/span>,\u00a0Jelinek<\/span>\u00a0HF<\/span><\/span>,\u00a0Alsafar<\/span>\u00a0H<\/span><\/span>,\u00a0et al<\/span>.\u00a0Genomics and epigenomics of gestational diabetes mellitus: Understanding the molecular pathways of the disease pathogenesis<\/span>.\u00a0Int J Mol Sci<\/em><\/span>.\u00a02022<\/span>;23<\/span>:3514<\/span>.\u00a0DOI<\/span>:\u00a010.3390\/ijms23073514<\/span>.<\/p>\r\n

31.<\/span>\u00a0Santamaria<\/span>\u00a0A<\/span><\/span>,\u00a0Cignini<\/span>\u00a0P<\/span><\/span>,\u00a0Trapanese<\/span>\u00a0A<\/span><\/span>,\u00a0Bonalumi<\/span>\u00a0S<\/span><\/span>.\u00a0Current strategy for detection and diagnosis of hyperglycemic disorders in pregnancy<\/span>.\u00a0J Prenat Med<\/em><\/span>.\u00a02011<\/span>;5<\/span>:15<\/span>\u20137<\/span>.<\/p>\r\n

32.<\/span>\u00a0Catalano<\/span>\u00a0PM<\/span><\/span>.\u00a0Trying to understand gestational diabetes<\/span>.\u00a0Diabet Med<\/em><\/span>.\u00a02014<\/span>;31<\/span>:273<\/span>\u201381<\/span>.\u00a0DOI<\/span>:\u00a010.1111\/dme.12381<\/span>.<\/p>\r\n

33.<\/span>\u00a0Sibiak<\/span>\u00a0R<\/span><\/span>,\u00a0Jankowski<\/span>\u00a0M<\/span><\/span>,\u00a0Gutaj<\/span>\u00a0P<\/span><\/span>,\u00a0et al<\/span>.\u00a0Placental lactogen as a marker of maternal obesity, diabetes, and fetal growth abnormalities: Current knowledge and clinical perspectives<\/span>.\u00a0J Clin Med<\/em><\/span>.\u00a02020<\/span>;9<\/span>:1142<\/span>.\u00a0DOI<\/span>:\u00a010.3390\/jcm9041142<\/span>.<\/p>\r\n

34.<\/span>\u00a0Harris<\/span>\u00a0M<\/span><\/span>.\u00a0Classification, diagnostic criteria, and screening for diabetes<\/span>.\u00a0In<\/span>:\u00a0Diabetes in America<\/em><\/span>.\u00a0Vol<\/span>.\u00a02<\/span>.\u00a01995<\/span>;95<\/span>\u20131468<\/span>.<\/p>\r\n

35.<\/span>\u00a0Carpenter<\/span>\u00a0M<\/span><\/span>,\u00a0Coustan<\/span>\u00a0D<\/span><\/span>.\u00a0Criteria for screening tests for gestational diabetes<\/span>.\u00a0Am J Obstet Gynecol<\/em><\/span>.\u00a01982<\/span>;144<\/span>:768<\/span>\u201373<\/span>.<\/p>\r\n

36.<\/span>International Association of Diabetes and Pregnancy Study Groups Consensus Panel,<\/span><\/span><\/span>Metzger<\/span>\u00a0BE<\/span><\/span>,\u00a0Gabbe<\/span>\u00a0SG<\/span><\/span>,\u00a0et al<\/span>.\u00a0International Association of Diabetes and Pregnancy Study Groups recommendations on the diagnosis and classification of hyperglycemia in pregnancy<\/span>.\u00a0Diabetes Care<\/em><\/span>.\u00a02010<\/span>;33<\/span>:676<\/span>\u201382<\/span>.\u00a0DOI<\/span>:\u00a010.2337\/dc09-1848<\/span>.<\/p>\r\n

37.<\/span>\u00a0Rassie<\/span>\u00a0K<\/span><\/span>,\u00a0Giri<\/span>\u00a0R<\/span><\/span>,\u00a0Joham<\/span>\u00a0AE<\/span><\/span>,\u00a0et al<\/span>.\u00a0Human placental lactogen in relation to maternal metabolic health and fetal outcomes: A systematic review and meta-analysis<\/span>.\u00a0Int J Mol Sci<\/em><\/span>.\u00a02022<\/span>;23<\/span>:15621<\/span>.\u00a0DOI<\/span>:\u00a010.3390\/ijms232415621<\/span>.<\/p>\r\n

38.<\/span>\u00a0Ruiz-Palacios<\/span>\u00a0M<\/span><\/span>,\u00a0Ruiz-Alcaraz<\/span>\u00a0AJ<\/span><\/span>,\u00a0Sanchez-Campillo<\/span>\u00a0M<\/span><\/span>,\u00a0Larqu\u00e9<\/span>\u00a0E<\/span><\/span>.\u00a0Role of insulin in placental transport of nutrients in gestational diabetes mellitus<\/span>.\u00a0Ann Nutr Metab<\/em><\/span>.\u00a02017<\/span>;70<\/span>:16<\/span>\u201325<\/span>.\u00a0DOI<\/span>:\u00a010.1159\/000455904<\/span>.<\/p>\r\n

39.<\/span>\u00a0White<\/span>\u00a0UA<\/span><\/span>,\u00a0Maier<\/span>\u00a0J<\/span><\/span>,\u00a0Zhao<\/span>\u00a0P<\/span><\/span>,\u00a0et al<\/span>.\u00a0The modulation of adiponectin by STAT5-activating hormones<\/span>.\u00a0Am J Physiol Endocrinol Metab<\/em><\/span>.\u00a02016<\/span>;310<\/span>:E129<\/span>\u201336<\/span>.\u00a0DOI<\/span>:\u00a010.1152\/ajpendo.00068.2015<\/span>.<\/p>\r\n

40.<\/span>\u00a0Meng<\/span>\u00a0Q<\/span><\/span>,\u00a0Qi<\/span>\u00a0X<\/span><\/span>,\u00a0Chao<\/span>\u00a0Y<\/span><\/span>,\u00a0et al<\/span>.\u00a0IRS1\/PI3K\/AKT pathway signal involved in the regulation of glycolipid metabolic abnormalities by Mulberry (Morus Alba<\/em>\u00a0L.) leaf extracts in 3T3-L1 adipocytes<\/span>.\u00a0Chin Med<\/em><\/span>.\u00a02020<\/span>;15<\/span>:1<\/span>.\u00a0DOI<\/span>:\u00a010.1186\/s13020-019-0281-6<\/span>.<\/p>\r\n

41.<\/span>\u00a0Barbour<\/span>\u00a0LA<\/span><\/span>,\u00a0Mizanoor Rahman<\/span>\u00a0S<\/span><\/span>,\u00a0Gurevich<\/span>\u00a0I<\/span><\/span>,\u00a0et al<\/span>.\u00a0Increased P85alpha is a potent negative regulator of skeletal muscle insulin signaling and induces in vivo insulin resistance associated with growth hormone excess<\/span>.\u00a0J Biol Chem<\/em><\/span>.\u00a02005<\/span>;280<\/span>:37489<\/span>\u201394<\/span>.\u00a0DOI<\/span>:\u00a010.1074\/jbc.M506967200<\/span>.<\/p>\r\n

42.<\/span>\u00a0Lepercq<\/span>\u00a0J<\/span><\/span>,\u00a0Cauzac<\/span>\u00a0M<\/span><\/span>,\u00a0Lahlou<\/span>\u00a0N<\/span><\/span>,\u00a0et al<\/span>.\u00a0Overexpression of placental leptin in diabetic pregnancy: A critical role for insulin<\/span>.\u00a0Diabetes<\/em><\/span>.\u00a01998<\/span>;47<\/span>:847<\/span>\u201350<\/span>.\u00a0DOI<\/span>:\u00a010.2337\/diabetes.47.5.847<\/span>.<\/p>\r\n

43.<\/span>\u00a0Kara<\/span>\u00a0M<\/span><\/span>,\u00a0Orbak<\/span>\u00a0Z<\/span><\/span>,\u00a0D\u00f6neray<\/span>\u00a0H<\/span><\/span>,\u00a0et al<\/span>.\u00a0The relationship between skinfold thickness and leptin, ghrelin, adiponectin, and resistin levels in infants of diabetic mothers<\/span>.\u00a0Fetal Pediatr Pathol<\/em><\/span>.\u00a02017<\/span>;36<\/span>:1<\/span>\u20137<\/span>.\u00a0DOI<\/span>:\u00a010.1080\/15513815.2016.1217960<\/span>.<\/p>\r\n

44.<\/span>\u00a0Abell<\/span>\u00a0SK<\/span><\/span>,\u00a0De Courten<\/span>\u00a0B<\/span><\/span>,\u00a0Boyle<\/span>\u00a0JA<\/span><\/span>,\u00a0Teede<\/span>\u00a0HJ<\/span><\/span>.\u00a0Inflammatory and other biomarkers: Role in pathophysiology and prediction of gestational diabetes mellitus<\/span>.\u00a0Int J Mol Sci<\/em><\/span>.\u00a02015<\/span>;16<\/span>:13442<\/span>\u201373<\/span>.\u00a0DOI<\/span>:\u00a010.3390\/ijms160613442<\/span>.<\/p>\r\n

45.<\/span>\u00a0Catalano<\/span>\u00a0PM<\/span><\/span>,\u00a0Nizielski<\/span>\u00a0SE<\/span><\/span>,\u00a0Shao<\/span>\u00a0J<\/span><\/span>,\u00a0et al<\/span>.\u00a0Downregulated IRS-1 and PPARgamma in obese women with gestational diabetes: Relationship to FFA during pregnancy<\/span>.\u00a0Am J Physiol Endocrinol Metab<\/em><\/span>.\u00a02002<\/span>;282<\/span>:E522<\/span>\u201333. <\/span>DOI<\/span>:\u00a010.1152\/ajpendo.00124.2001<\/span>.<\/p>\r\n

46.<\/span>\u00a0Lekva<\/span>\u00a0T<\/span><\/span>,\u00a0Norwitz<\/span>\u00a0ER<\/span><\/span>,\u00a0Aukrust<\/span>\u00a0P<\/span><\/span>,\u00a0Ueland<\/span>\u00a0T<\/span><\/span>.\u00a0Impact of systemic inflammation on the progression of gestational diabetes mellitus<\/span>.\u00a0Curr Diab Rep<\/em><\/span>.\u00a02016<\/span>;16<\/span>:26<\/span>.\u00a0DOI<\/span>:\u00a010.1007\/s11892-016-0715-9<\/span>.<\/p>\r\n

47.<\/span>\u00a0P\u00e9rez-P\u00e9rez<\/span>\u00a0A<\/span><\/span>,\u00a0Vilari\u00f1o-Garc\u00eda<\/span>\u00a0T<\/span><\/span>,\u00a0Guadix<\/span>\u00a0P<\/span><\/span>,\u00a0et al<\/span>.\u00a0Leptin and nutrition in gestational diabetes. <\/span>Nutrients. <\/em><\/span>2020<\/span>;12<\/span>:1970. <\/span>DOI<\/span>:\u00a010.3390\/nu12071970<\/span>.<\/p>\r\n

48.<\/span>\u00a0Roca-Rodr\u00edguez<\/span>\u00a0MDM<\/span><\/span>,\u00a0Ramos-Garc\u00eda<\/span>\u00a0P<\/span><\/span>,\u00a0L\u00f3pez-Tinoco<\/span>\u00a0C<\/span><\/span>,\u00a0Aguilar-Diosdado<\/span>\u00a0M<\/span><\/span>.\u00a0Significance of serum-plasma Leptin profile during pregnancy in gestational diabetes mellitus: A systematic review and meta-analysis<\/span>.\u00a0Journal of clinical medicine<\/em><\/span>.\u00a02022<\/span>;11<\/span>:2433<\/span>.\u00a0DOI<\/span>:\u00a010.3390\/jcm11092433<\/span>.<\/p>\r\n

49.<\/span>\u00a0Varastehpour<\/span>\u00a0A<\/span><\/span>,\u00a0Radaelli<\/span>\u00a0T<\/span><\/span>,\u00a0Minium<\/span>\u00a0J<\/span><\/span>,\u00a0et al<\/span>.\u00a0Activation of phospholipase A2 is associated with generation of placental lipid signals and fetal obesity<\/span>.\u00a0J Clin Endocrinol Metab<\/em><\/span>.\u00a02006<\/span>;91<\/span>:248<\/span>\u201355<\/span>.\u00a0DOI<\/span>:\u00a010.1210\/jc.2005-0873<\/span>.<\/p>\r\n

50.<\/span>\u00a0Fasshauer<\/span>\u00a0M<\/span><\/span>,\u00a0Bl\u00fcher<\/span>\u00a0M<\/span><\/span>,\u00a0Stumvoll<\/span>\u00a0M<\/span><\/span>.\u00a0Adipokines in gestational diabetes<\/span>.\u00a0Lancet Diabetes Endocrinol<\/em><\/span>.\u00a02014<\/span>;2<\/span>:488<\/span>\u201399<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/S2213-8587(13)70176-1<\/span>.<\/p>\r\n

51.<\/span>\u00a0Bi<\/span>\u00a0S<\/span><\/span>,\u00a0Gavrilova<\/span>\u00a0O<\/span><\/span>,\u00a0Gong<\/span>\u00a0DW<\/span><\/span>,\u00a0et al<\/span>.\u00a0Identification of a placental enhancer for the human leptin gene<\/span>.\u00a0J Biol Chem<\/em><\/span>.\u00a01997<\/span>;272<\/span>:30583<\/span>\u20138<\/span>.\u00a0DOI<\/span>:\u00a010.1074\/jbc.272.48.30583<\/span>.<\/p>\r\n

52.<\/span>\u00a0Ashworth<\/span>\u00a0CJ<\/span><\/span>,\u00a0Hoggard<\/span>\u00a0N<\/span><\/span>,\u00a0Thomas<\/span>\u00a0L<\/span><\/span>,\u00a0et al<\/span>.\u00a0Placental leptin<\/span>.\u00a0Rev Reprod<\/em><\/span>.\u00a02000<\/span>;5<\/span>:18<\/span>\u201324<\/span>.\u00a0DOI<\/span>:\u00a010.1530\/ror.0.0050018<\/span>.<\/p>\r\n

53.<\/span>\u00a0Henson<\/span>\u00a0MC<\/span><\/span>,\u00a0Castracane<\/span>\u00a0VD<\/span><\/span>.\u00a0Leptin in pregnancy: An update<\/span>.\u00a0Biol Reprod<\/em><\/span>.\u00a02006<\/span>;74<\/span>:218<\/span>\u201329. <\/span>DOI<\/span>:\u00a010.1095\/biolreprod.105.045120<\/span>.<\/p>\r\n

54.<\/span>\u00a0Al-Badri<\/span>\u00a0MR<\/span><\/span>,\u00a0Zantout<\/span>\u00a0MS<\/span><\/span>,\u00a0Azar<\/span>\u00a0ST<\/span><\/span>.\u00a0The role of adipokines in gestational diabetes mellitus<\/span>.\u00a0Ther Adv Endocrinol Metab<\/em><\/span>.\u00a02015<\/span>;6<\/span>:103<\/span>\u20138<\/span>.\u00a0DOI<\/span>:\u00a010.1177\/2042018815577039<\/span>.<\/p>\r\n

55.<\/span>\u00a0Radaelli<\/span>\u00a0T<\/span><\/span>,\u00a0Varastehpour<\/span>\u00a0A<\/span><\/span>,\u00a0Catalano<\/span>\u00a0P<\/span><\/span>,\u00a0Hauguel-de Mouzon<\/span>\u00a0S<\/span><\/span>.\u00a0Gestational diabetes induces placental genes for chronic stress and inflammatory pathways<\/span>.\u00a0Diabetes<\/em><\/span>.\u00a02003<\/span>;52<\/span>:2951<\/span>\u20138<\/span>.\u00a0DOI<\/span>:\u00a010.2337\/diabetes.52.12.2951<\/span>.<\/p>\r\n

56.<\/span>\u00a0Morisset<\/span>\u00a0A-S<\/span><\/span>,\u00a0Dub\u00e9<\/span>\u00a0M-C<\/span><\/span>,\u00a0C\u00f4t\u00e9<\/span>\u00a0JA<\/span><\/span>,\u00a0et al<\/span>.\u00a0Circulating interleukin-6 concentrations during and after gestational diabetes mellitus<\/span>.\u00a0Acta Obstet Gynecol Scand<\/em><\/span>.\u00a02011<\/span>;90<\/span>:524<\/span>\u201330<\/span>.\u00a0DOI<\/span>:\u00a010.1111\/j.1600-0412.2011.01094.x<\/span>.<\/p>\r\n

57.<\/span>\u00a0Jones<\/span>\u00a0HN<\/span><\/span>,\u00a0Jansson<\/span>\u00a0T<\/span><\/span>,\u00a0Powell<\/span>\u00a0TL<\/span><\/span>.\u00a0IL-6 stimulates system A amino acid transporter activity in trophoblast cells through STAT3 and increased expression of SNAT2<\/span>.\u00a0Am J Physiol Cell Physiol<\/em><\/span>.\u00a02009<\/span>;297<\/span>:C1228<\/span>\u201335. <\/span>DOI<\/span>:\u00a010.1152\/ajpcell.00195.2009<\/span>.<\/p>\r\n

58.<\/span>\u00a0Bawah<\/span>\u00a0AT<\/span><\/span>,\u00a0Seini<\/span>\u00a0MM<\/span><\/span>,\u00a0Abaka-Yawason<\/span>\u00a0A<\/span><\/span>,\u00a0et al<\/span>.\u00a0Resistin and visfatin as useful predictors of gestational diabetes mellitus<\/span>.\u00a0Lipids Health Dis<\/em><\/span>.\u00a02019<\/span>;18<\/span>:221<\/span>.\u00a0DOI<\/span>:\u00a010.1186\/s12944-019-1169-2<\/span>.<\/p>\r\n

59.<\/span>\u00a0Stanirowski<\/span>\u00a0PJ<\/span><\/span>,\u00a0Szukiewicz<\/span>\u00a0D<\/span><\/span>,\u00a0Pazura-Turowska<\/span>\u00a0M<\/span><\/span>,\u00a0et al<\/span>.\u00a0Placental expression of glucose transporter proteins in pregnancies complicated by gestational and pregestational diabetes mellitus<\/span>.\u00a0Can J Diabetes<\/em><\/span>.\u00a02018<\/span>;42<\/span>:209<\/span>\u201317<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.jcjd.2017.04.008<\/span>.<\/p>\r\n

60.<\/span>\u00a0Vitoratos<\/span>\u00a0N<\/span><\/span>,\u00a0Valsamakis<\/span>\u00a0G<\/span><\/span>,\u00a0Mastorakos<\/span>\u00a0G<\/span><\/span>,\u00a0et al<\/span>.\u00a0Pre- and early post-partum adiponectin and interleukin-1beta levels in women with and without gestational diabetes<\/span>.\u00a0Hormones (Athens)<\/em><\/span>.\u00a02008<\/span>;7<\/span>:230<\/span>\u20136. <\/span>DOI<\/span>:\u00a010.14310\/horm.2002.1202<\/span>.<\/p>\r\n

61.<\/span>\u00a0Lappas<\/span>\u00a0M<\/span><\/span>.\u00a0Activation of inflammasomes in adipose tissue of women with gestational diabetes<\/span>.\u00a0Mol Cell Endocrinol<\/em><\/span>.\u00a02014<\/span>;382<\/span>:74<\/span>\u201383<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.mce.2013.09.011<\/span>.<\/p>\r\n

62.<\/span>\u00a0Hu<\/span>\u00a0SM<\/span><\/span>,\u00a0Chen<\/span>\u00a0MS<\/span><\/span>,\u00a0Tan<\/span>\u00a0HZ<\/span><\/span>.\u00a0Maternal serum level of resistin is associated with risk for gestational diabetes mellitus: A meta-analysis<\/span>.\u00a0World J Clin Cases<\/em><\/span>.\u00a02019<\/span>;7<\/span>:585<\/span>\u201399<\/span>.\u00a0DOI<\/span>:\u00a010.12998\/wjcc.v7.i5.585<\/span>.<\/p>\r\n

63.<\/span>\u00a0Rusza\u0142a<\/span>\u00a0M<\/span><\/span>,\u00a0Niebrzydowska<\/span>\u00a0M<\/span><\/span>,\u00a0Pilszyk<\/span>\u00a0A<\/span><\/span>,\u00a0et al<\/span>.\u00a0Novel biomolecules in the pathogenesis of gestational diabetes mellitus<\/span>.\u00a0Int J Mol Sci<\/em><\/span>.\u00a02021<\/span>;22<\/span>:11578<\/span>.\u00a0DOI<\/span>:\u00a010.3390\/ijms222111578<\/span>.<\/p>\r\n

64.<\/span>\u00a0Choudhury<\/span>\u00a0AA<\/span><\/span>,\u00a0Devi Rajeswari<\/span>\u00a0V<\/span><\/span>.\u00a0Gestational diabetes mellitus - A metabolic and reproductive disorder<\/span>.\u00a0Biomed Pharmacother<\/em><\/span>.\u00a02021<\/span>;143<\/span>:112183<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.biopha.2021.112183<\/span>.<\/p>\r\n

65.<\/span>\u00a0Liong<\/span>\u00a0S<\/span><\/span>,\u00a0Lappas<\/span>\u00a0M<\/span><\/span>.\u00a0Lipopolysaccharide and double stranded viral RNA mediate insulin resistance and increase system a amino acid transport in human trophoblast cells in vitro<\/span>.\u00a0Placenta<\/em><\/span>.\u00a02017<\/span>;51<\/span>:18<\/span>\u201327. <\/span>DOI<\/span>:\u00a010.1016\/j.placenta.2017.01.124<\/span>.<\/p>\r\n

66.<\/span>\u00a0Liu<\/span>\u00a0X<\/span><\/span>,\u00a0Wang<\/span>\u00a0Y<\/span><\/span>.\u00a0Research progresses of the mechanism of insulin resistance in type II diabetes<\/span>.\u00a0E3S Web of Conferences<\/em><\/span>.\u00a02019<\/span>;78<\/span>:01006<\/span>.\u00a0DOI<\/span>:\u00a010.1051\/e3sconf\/20197801006<\/span>.<\/p>\r\n

67.<\/span>\u00a0Ueland<\/span>\u00a0T<\/span><\/span>,\u00a0Michelsen<\/span>\u00a0AE<\/span><\/span>,\u00a0Aukrust<\/span>\u00a0P<\/span><\/span>,\u00a0et al<\/span>.\u00a0Adipokines and macrophage markers during pregnancy \u2013 possible role for Scd163 in prediction and progression of gestational diabetes mellitus<\/span>.\u00a0Diabetes Metab Res Rev. <\/em><\/span>2018<\/span>;35<\/span>:e3114. <\/span>DOI<\/span>:\u00a010.1002\/dmrr.3114<\/span>.<\/p>\r\n

68.<\/span>\u00a0Yu<\/span>\u00a0J<\/span><\/span>,\u00a0Zhou<\/span>\u00a0Y<\/span><\/span>,\u00a0Gui<\/span>\u00a0J<\/span><\/span>,\u00a0et al<\/span>.\u00a0Assessment of the number and function of macrophages in the placenta of gestational diabetes mellitus patients<\/span>.\u00a0J Huazhong Univ Sci Technol Med Sci<\/em><\/span>.\u00a02013<\/span>;33<\/span>:725<\/span>\u20139<\/span>.\u00a0DOI<\/span>:\u00a010.1007\/s11596-013-1187-7<\/span>.<\/p>\r\n

69.<\/span>\u00a0Ehlers<\/span>\u00a0E<\/span><\/span>,\u00a0Talton<\/span>\u00a0OO<\/span><\/span>,\u00a0Schust<\/span>\u00a0DJ<\/span><\/span>,\u00a0Schulz<\/span>\u00a0LC<\/span><\/span>.\u00a0Placental structural abnormalities in gestational diabetes and when they develop: A scoping review<\/span>.\u00a0Placenta<\/em><\/span>.\u00a02021<\/span>;116<\/span>:58<\/span>\u201366<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.placenta.2021.04.005<\/span>.<\/p>\r\n

70.<\/span>\u00a0Burton<\/span>\u00a0GJ<\/span><\/span>,\u00a0Fowden<\/span>\u00a0AL<\/span><\/span>.\u00a0The placenta: A multifaceted, transient organ<\/span>.\u00a0Philos Trans R Soc Lond B Biol Sci. <\/em><\/span>2015<\/span>;370<\/span>:20140066. <\/span>DOI<\/span>:\u00a010.1098\/rstb.2014.0066<\/span>.<\/p>\r\n

71.<\/span>\u00a0Huynh<\/span>\u00a0J<\/span><\/span>,\u00a0Dawson<\/span>\u00a0D<\/span><\/span>,\u00a0Roberts<\/span>\u00a0D<\/span><\/span>,\u00a0Bentley-Lewis<\/span>\u00a0R<\/span><\/span>.\u00a0A systematic review of placental pathology in maternal diabetes mellitus<\/span>.\u00a0Placenta<\/em><\/span>.\u00a02015<\/span>;36<\/span>:101<\/span>\u201314<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.placenta.2014.11.021<\/span>.<\/p>\r\n

72.<\/span>\u00a0Carrasco-Wong<\/span>\u00a0I<\/span><\/span>,\u00a0Moller<\/span>\u00a0A<\/span><\/span>,\u00a0Giachini<\/span>\u00a0FR<\/span><\/span>,\u00a0et al<\/span>.\u00a0Placental structure in gestational diabetes mellitus<\/span>.\u00a0Biochim Biophys Acta Mol Basis Dis<\/em><\/span>.\u00a02020<\/span>;1866<\/span>:165535<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.bbadis.2019.165535<\/span>.<\/p>\r\n

73.<\/span>\u00a0Huynh<\/span>\u00a0J<\/span><\/span>,\u00a0Yamada<\/span>\u00a0J<\/span><\/span>,\u00a0Beauharnais<\/span>\u00a0C<\/span><\/span>,\u00a0et al<\/span>.\u00a0Type 1, type 2 and gestational diabetes mellitus differentially impact placental pathologic characteristics of uteroplacental malperfusion<\/span>.\u00a0Placenta<\/em><\/span>.\u00a02015<\/span>;36<\/span>:1161<\/span>\u20136. <\/span>DOI<\/span>:\u00a010.1016\/j.placenta.2015.08.004<\/span>.<\/p>\r\n

74.<\/span>\u00a0Cindrova-Davies<\/span>\u00a0T<\/span><\/span>,\u00a0Sferruzzi-Perri<\/span>\u00a0AN<\/span><\/span>.\u00a0Human placental development and function<\/span>.\u00a0Semin Cell Dev Biol. <\/em><\/span>2022<\/span>;131<\/span>:66<\/span>\u201377. <\/span>DOI<\/span>:\u00a010.1016\/j.semcdb.2022.03.039<\/span>.<\/p>\r\n

75.<\/span>\u00a0Wang<\/span>\u00a0K<\/span><\/span>,\u00a0Jiang<\/span>\u00a0Y<\/span><\/span>,\u00a0Chen<\/span>\u00a0D<\/span><\/span>,\u00a0Zheng<\/span>\u00a0J<\/span><\/span>.\u00a0Hypoxia enhances FGF2- and VEGF-stimulated human placental artery endothelial cell proliferation: Roles of MEK1\/2\/ERK1\/2 and PI3K\/AKT1 pathways<\/span>.\u00a0Placenta<\/em><\/span>.\u00a02009<\/span>;30<\/span>:1045<\/span>\u201351. <\/span>DOI<\/span>:\u00a010.1016\/j.placenta.2009.10.007<\/span>.<\/p>\r\n

76.<\/span>\u00a0Aires<\/span>\u00a0MB<\/span><\/span>,\u00a0Dos Santos<\/span>\u00a0ACV<\/span><\/span>.\u00a0Effects of maternal diabetes on trophoblast cells<\/span>.\u00a0World J Diabetes<\/em><\/span>.\u00a02015<\/span>;6<\/span>:338<\/span>\u201344<\/span>.\u00a0DOI<\/span>:\u00a010.4239\/wjd.v6.i2.338<\/span>.<\/p>\r\n

77.<\/span>\u00a0Magee<\/span>\u00a0TR<\/span><\/span>,\u00a0Ross<\/span>\u00a0MG<\/span><\/span>,\u00a0Wedekind<\/span>\u00a0L<\/span><\/span>,\u00a0et al<\/span>.\u00a0Gestational diabetes mellitus alters apoptotic and inflammatory gene expression of trophobasts from human term placenta<\/span>.\u00a0J Diabetes Complications<\/em><\/span>.\u00a02014<\/span>;28<\/span>:448<\/span>\u201359. <\/span>DOI<\/span>:\u00a010.1016\/j.jdiacomp.2014.03.010<\/span>.<\/p>\r\n

78.<\/span>\u00a0Valero<\/span>\u00a0P<\/span><\/span>,\u00a0Fuentes<\/span>\u00a0G<\/span><\/span>,\u00a0Cornejo<\/span>\u00a0M<\/span><\/span>,\u00a0et al<\/span>.\u00a0Exposome and foetoplacental vascular dysfunction in gestational diabetes mellitus<\/span>.\u00a0Mol Aspects Med<\/em><\/span>.\u00a02022<\/span>;87<\/span>:101019<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.mam.2021.101019<\/span>.<\/p>\r\n

79.<\/span>\u00a0Yavuz<\/span>\u00a0D<\/span><\/span>,\u00a0Balsak<\/span>\u00a0D<\/span><\/span>,\u00a0Ekinci<\/span>\u00a0C<\/span><\/span>,\u00a0et al<\/span>.\u00a0Expression of VEGF and CD68 in the placenta of gestational diabetic mothers (immunohistochemistry and ultrastructural study)<\/span>.\u00a0Int J Morphol<\/em><\/span>.\u00a02015<\/span>;33<\/span>:522<\/span>\u20136<\/span>.\u00a0DOI<\/span>:\u00a010.4067\/S0717-95022015000200018<\/span>.<\/p>\r\n

80.<\/span>\u00a0Oh<\/span>\u00a0M-J<\/span><\/span>,\u00a0Zhang<\/span>\u00a0C<\/span><\/span>,\u00a0LeMaster<\/span>\u00a0E<\/span><\/span>,\u00a0et al<\/span>.\u00a0Oxidized LDL signals through Rho-GTPase to induce endothelial cell stiffening and promote capillary formation<\/span>.\u00a0J Lipid Res<\/em><\/span>.\u00a02016<\/span>;57<\/span>:791<\/span>\u2013808<\/span>.\u00a0DOI<\/span>:\u00a010.1194\/jlr.M062539<\/span>.<\/p>\r\n

81.<\/span>\u00a0Mart\u00ednez-Jim\u00e9nez<\/span>\u00a0MA<\/span><\/span>,\u00a0Aguilar-Garc\u00eda<\/span>\u00a0J<\/span><\/span>,\u00a0Vald\u00e9s-Rodr\u00edguez<\/span>\u00a0R<\/span><\/span>,\u00a0et al<\/span>.\u00a0Local use of insulin in wounds of diabetic patients<\/span>.\u00a0Plast Reconst Surg<\/em><\/span>.\u00a02013<\/span>;132<\/span>:1015e<\/span>\u20139e<\/span>.\u00a0DOI<\/span>:\u00a010.1097\/PRS.0b013e3182a806f0<\/span>.<\/p>\r\n

82.<\/span>\u00a0Leach<\/span>\u00a0L<\/span><\/span>,\u00a0Taylor<\/span>\u00a0A<\/span><\/span>,\u00a0Sciota<\/span>\u00a0F<\/span><\/span>.\u00a0Vascular dysfunction in the diabetic placenta: Causes and consequences<\/span>.\u00a0J Anat<\/em><\/span>.\u00a02009<\/span>;215<\/span>:69<\/span>\u201376<\/span>.\u00a0DOI<\/span>:\u00a010.1111\/j.1469-7580.2009.01098.x<\/span>.<\/p>\r\n

83.<\/span>\u00a0Gorkem<\/span>\u00a0U<\/span><\/span>,\u00a0Togrul<\/span>\u00a0C<\/span><\/span>,\u00a0Arslan<\/span>\u00a0E<\/span><\/span>.\u00a0Relationship between elevated serum level of placental growth factor and status of gestational diabetes mellitus<\/span>.\u00a0J Matern Fetal Neonatal Med<\/em><\/span>.\u00a02020<\/span>;33<\/span>:4159<\/span>\u201363<\/span>.\u00a0DOI<\/span>:\u00a010.1080\/14767058.2019.1598361<\/span>.<\/p>\r\n

84.<\/span>\u00a0Nuzzo<\/span>\u00a0AM<\/span><\/span>,\u00a0Giuffrida<\/span>\u00a0D<\/span><\/span>,\u00a0Moretti<\/span>\u00a0L<\/span><\/span>,\u00a0et al<\/span>.\u00a0Placental and maternal sFlt1\/PlGF expression in gestational diabetes mellitus<\/span>.\u00a0Sci Rep<\/em><\/span>.\u00a02021<\/span>;11<\/span>:2312<\/span>.\u00a0DOI<\/span>:\u00a010.1038\/s41598-021-81785-5<\/span>.<\/p>\r\n

85.<\/span>\u00a0Hayes Ryan<\/span>\u00a0D<\/span><\/span>,\u00a0McCarthy<\/span>\u00a0FP<\/span><\/span>,\u00a0O\u2019Donoghue<\/span>\u00a0K<\/span><\/span>,\u00a0Kenny<\/span>\u00a0LC<\/span><\/span>.\u00a0Placental growth factor: A review of literature and future applications<\/span>.\u00a0Pregnancy Hypertens<\/em><\/span>.\u00a02018<\/span>;14<\/span>:260<\/span>\u20134<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.preghy.2018.03.003<\/span>.<\/p>\r\n

86.<\/span>\u00a0Cornejo<\/span>\u00a0M<\/span><\/span>,\u00a0Fuentes<\/span>\u00a0G<\/span><\/span>,\u00a0Valero<\/span>\u00a0P<\/span><\/span>,\u00a0et al<\/span>.\u00a0Gestational diabesity and foetoplacental vascular dysfunction<\/span>.\u00a0Acta Physiol (Oxf)<\/em><\/span>.\u00a02021<\/span>;232<\/span>:e13671<\/span>.\u00a0DOI<\/span>:\u00a010.1111\/apha.13671<\/span>.<\/p>\r\n

87.<\/span>\u00a0Guzm\u00e1n-Guti\u00e9rrez<\/span>\u00a0E<\/span><\/span>,\u00a0Arroyo<\/span>\u00a0P<\/span><\/span>,\u00a0Salsoso<\/span>\u00a0R<\/span><\/span>,\u00a0et al<\/span>.\u00a0Role of insulin and adenosine in the human placenta microvascular and macrovascular endothelial cell dysfunction in gestational diabetes mellitus. <\/span>Microcirculation. <\/em><\/span>2014<\/span>;21<\/span>:26<\/span>\u201337<\/span>. DOI<\/span>:\u00a010.1111\/micc.12077<\/span>.<\/p>\r\n

88.<\/span>\u00a0Clark<\/span>\u00a0NC<\/span><\/span>,\u00a0Pru<\/span>\u00a0CA<\/span><\/span>,\u00a0Pru<\/span>\u00a0JK<\/span><\/span>.\u00a0Novel regulators of hemodynamics in the pregnant uterus<\/span>.\u00a0Prog Mol Biol Transl Sci. <\/em><\/span>2017<\/span>;145<\/span>:181<\/span>\u2013216. <\/span>DOI<\/span>:\u00a010.1016\/bs.pmbts.2016.12.007<\/span>.<\/p>\r\n

89.<\/span>\u00a0Sun<\/span>\u00a0X<\/span><\/span>,\u00a0Qu<\/span>\u00a0T<\/span><\/span>,\u00a0He<\/span>\u00a0X<\/span><\/span>,\u00a0et al<\/span>.\u00a0Screening of differentially expressed proteins from syncytiotrophoblast for severe early-onset preeclampsia in women with gestational diabetes mellitus using tandem mass tag quantitative proteomics<\/span>.\u00a0BMC Pregnancy Childbirth<\/em><\/span>.\u00a02018<\/span>;18<\/span>:437<\/span>.\u00a0DOI<\/span>:\u00a010.1186\/s12884-018-2066-9<\/span>.<\/p>\r\n

90.<\/span>\u00a0Chauhan<\/span>\u00a0M<\/span><\/span>,\u00a0Balakrishnan<\/span>\u00a0M<\/span><\/span>,\u00a0Chan<\/span>\u00a0R<\/span><\/span>,\u00a0Yallampalli<\/span>\u00a0C<\/span><\/span>.\u00a0Adrenomedullin 2 (ADM2) regulates mucin 1 at the maternal-fetal interface in human pregnancy<\/span>.\u00a0Biol Reprod<\/em><\/span>.\u00a02015<\/span>;93<\/span>:136<\/span>.\u00a0DOI<\/span>:\u00a010.1095\/biolreprod.115.134296<\/span>.<\/p>\r\n

91.<\/span>\u00a0Bowman<\/span>\u00a0CJ<\/span><\/span>,\u00a0Streck<\/span>\u00a0RD<\/span><\/span>,\u00a0Chapin<\/span>\u00a0RE<\/span><\/span>.\u00a0Maternal-placental insulin-like growth factor (IGF) signaling and its importance to normal embryo-fetal development<\/span>.\u00a0Birth Defects Res B Dev Reprod Toxicol<\/em><\/span>.\u00a02010<\/span>;89<\/span>:339<\/span>\u201349. <\/span>DOI<\/span>:\u00a010.1002\/bdrb.20249<\/span>.<\/p>\r\n

92.<\/span>\u00a0Jansson<\/span>\u00a0T<\/span><\/span>,\u00a0Powell<\/span>\u00a0TL<\/span><\/span>.\u00a0Human placental transport in altered fetal growth: Does the placenta function as a nutrient sensor? - A review<\/span>.\u00a0Placenta<\/em><\/span>.\u00a02006<\/span>;27<\/span>:91<\/span>\u20137<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.placenta.2005.11.010<\/span>.<\/p>\r\n

93.<\/span>\u00a0Godfrey<\/span>\u00a0KM<\/span><\/span>,\u00a0Matthews<\/span>\u00a0N<\/span><\/span>,\u00a0Glazier<\/span>\u00a0J<\/span><\/span>,\u00a0et al<\/span>.\u00a0Neutral amino acid uptake by the microvillous plasma membrane of the human placenta is inversely related to fetal size at birth in normal pregnancy<\/span>.\u00a0J Clin Endocrinol Metab<\/em><\/span>.\u00a01998<\/span>;83<\/span>:3320<\/span>\u20136<\/span>.\u00a0DOI<\/span>:\u00a010.1210\/jcem.83.9.5132<\/span>.<\/p>\r\n

94.<\/span>\u00a0Wang<\/span>\u00a0H<\/span><\/span>,\u00a0Huang<\/span>\u00a0B<\/span><\/span>,\u00a0Hou<\/span>\u00a0A<\/span><\/span>,\u00a0et al<\/span>.\u00a0High NOV\/CCN3 expression during high-fat diet pregnancy in mice affects GLUT3 expression and the mTOR pathway<\/span>.\u00a0Am J Physiol Endocrinol Metab<\/em><\/span>.\u00a02021<\/span>;320<\/span>:E786<\/span>\u201396<\/span>.\u00a0DOI<\/span>:\u00a010.1152\/ajpendo.00230.2020<\/span>.<\/p>\r\n

95.<\/span>\u00a0Gallo<\/span>\u00a0LA<\/span><\/span>,\u00a0Barrett<\/span>\u00a0HL<\/span><\/span>,\u00a0Dekker Nitert<\/span>\u00a0M<\/span><\/span>.\u00a0Placental transport and metabolism of energy substrates in maternal obesity and diabetes<\/span>.\u00a0Placenta<\/em><\/span>.\u00a02017<\/span>;54<\/span>:59<\/span>\u201367<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.placenta.2016.12.006<\/span>.<\/p>\r\n

96.<\/span>\u00a0Lager<\/span>\u00a0S<\/span><\/span>,\u00a0Jansson<\/span>\u00a0N<\/span><\/span>,\u00a0Olsson<\/span>\u00a0AL<\/span><\/span>,\u00a0et al<\/span>.\u00a0Effect of IL-6 and TNF-\u0391 on fatty acid uptake in cultured human primary Trophoblast cells<\/span>.\u00a0Placenta<\/em><\/span>.\u00a02011<\/span>;32<\/span>:121<\/span>\u20137<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.placenta.2010.10.012<\/span>.<\/p>\r\n

97.<\/span>\u00a0Kauma<\/span>\u00a0SW<\/span><\/span>,\u00a0Herman<\/span>\u00a0K<\/span><\/span>,\u00a0Wang<\/span>\u00a0Y<\/span><\/span>,\u00a0Walsh<\/span>\u00a0SW<\/span><\/span>.\u00a0Differential mRNA expression and production of interleukin-6 in placental trophoblast and villous core compartments<\/span>.\u00a0Am J Reprod Immunol<\/em><\/span>.\u00a01993<\/span>;30<\/span>:131<\/span>\u20135<\/span>.\u00a0DOI<\/span>:\u00a010.1111\/j.1600-0897.1993.tb00613.x<\/span>.<\/p>\r\n

98.<\/span>\u00a0Desoye<\/span>\u00a0G<\/span><\/span>,\u00a0Wells<\/span>\u00a0JCK<\/span><\/span>.\u00a0Pregnancies in diabetes and obesity: The capacity-load model of placental adaptation. <\/span>Diabetes<\/em><\/span>.\u00a02021<\/span>;70<\/span>:823<\/span>\u201330<\/span>.\u00a0DOI<\/span>:\u00a010.2337\/db20-1111<\/span>.<\/p>\r\n

99.<\/span>\u00a0Elshani<\/span>\u00a0B<\/span><\/span>,\u00a0Kotori<\/span>\u00a0V<\/span><\/span>,\u00a0Daci<\/span>\u00a0A<\/span><\/span>.\u00a0Role of omega-3 polyunsaturated fatty acids in gestational diabetes, maternal and fetal insights: Current use and future directions<\/span>.\u00a0J Matern Fetal Neonatal Med<\/em><\/span>.\u00a02021<\/span>;34<\/span>:124<\/span>\u201336. <\/span>DOI<\/span>:\u00a010.1080\/14767058.2019.1593361<\/span>.<\/p>\r\n

100.<\/span>\u00a0Ara\u00fajo<\/span>\u00a0JR<\/span><\/span>,\u00a0Keating<\/span>\u00a0E<\/span><\/span>,\u00a0Martel<\/span>\u00a0F<\/span><\/span>.\u00a0Impact of gestational diabetes mellitus in the maternal-to-fetal transport of nutrients<\/span>.\u00a0Curr Diab Rep<\/em><\/span>.\u00a02015<\/span>;15<\/span>:569<\/span>.\u00a0DOI<\/span>:\u00a010.1007\/s11892-014-0569-y<\/span>.<\/p>\r\n

101.<\/span>\u00a0Osmond<\/span>\u00a0DT<\/span><\/span>,\u00a0Nolan<\/span>\u00a0CJ<\/span><\/span>,\u00a0King<\/span>\u00a0RG<\/span><\/span>,\u00a0et al<\/span>.\u00a0Effects of gestational diabetes on human placental glucose uptake, transfer, and utilisation<\/span>.\u00a0Diabetologia<\/em><\/span>.\u00a02000<\/span>;43<\/span>:576<\/span>\u201382<\/span>.\u00a0DOI<\/span>:\u00a010.1007\/s001250051346<\/span>.<\/p>\r\n

102.<\/span>\u00a0Hiden<\/span>\u00a0U<\/span><\/span>,\u00a0Lang<\/span>\u00a0I<\/span><\/span>,\u00a0Ghaffari-Tabrizi<\/span>\u00a0N<\/span><\/span>,\u00a0et al<\/span>.\u00a0Insulin action on the human placental endothelium in normal and diabetic pregnancy<\/span>.\u00a0Curr Vasc Pharmacol<\/em><\/span>.\u00a02009<\/span>;7<\/span>:460<\/span>\u20136<\/span>.\u00a0DOI<\/span>:\u00a010.2174\/157016109789043973<\/span>.<\/p>\r\n

103.<\/span>\u00a0Pan<\/span>\u00a0X<\/span><\/span>,\u00a0Jin<\/span>\u00a0X<\/span><\/span>,\u00a0Wang<\/span>\u00a0J<\/span><\/span>,\u00a0et al<\/span>.\u00a0Placenta inflammation is closely associated with gestational diabetes mellitus<\/span>.\u00a0Am J Transl Res<\/em><\/span>.\u00a02021<\/span>;13<\/span>:4068<\/span>\u201379<\/span>.<\/p>\r\n

104.<\/span>\u00a0Du<\/span>\u00a0M<\/span><\/span>,\u00a0Yan<\/span>\u00a0X<\/span><\/span>,\u00a0Tong<\/span>\u00a0JF<\/span><\/span>,\u00a0et al<\/span>.\u00a0Maternal obesity, inflammation, and fetal skeletal muscle development<\/span>.\u00a0Biol Reprod<\/em><\/span>.\u00a02010<\/span>;82<\/span>:4<\/span>\u201312. <\/span>DOI<\/span>:\u00a010.1095\/biolreprod.109.077099<\/span>.<\/p>\r\n

105.<\/span>\u00a0Araujo J\u00fanior<\/span>\u00a0E<\/span><\/span>,\u00a0Peixoto<\/span>\u00a0A<\/span><\/span>,\u00a0Zamarian<\/span>\u00a0A<\/span><\/span>,\u00a0et al<\/span>.\u00a0Macrosomia<\/span>.\u00a0Best Pract Res Clin Obstet Gynaecol<\/em><\/span>.\u00a02017<\/span>;38<\/span>:83<\/span>\u201396. <\/span>DOI<\/span>:\u00a010.1016\/j.bpobgyn.2016.08.003<\/span>.<\/p>\r\n

106.<\/span>\u00a0Kaaja<\/span>\u00a0R<\/span><\/span>,\u00a0R\u00f6nnemaa<\/span>\u00a0T<\/span><\/span>.\u00a0Gestational diabetes: Pathogenesis and consequences to mother and offspring<\/span>.\u00a0Rev Diabet Stud<\/em><\/span>.\u00a02008<\/span>;5<\/span>:194<\/span>\u2013202<\/span>.\u00a0DOI<\/span>:\u00a010.1900\/RDS.2008.5.194<\/span>.<\/p>\r\n

107.<\/span>\u00a0Kc<\/span>\u00a0K<\/span><\/span>,\u00a0Shakya<\/span>\u00a0S<\/span><\/span>,\u00a0Zhang<\/span>\u00a0H<\/span><\/span>.\u00a0Gestational diabetes mellitus and macrosomia: A literature review<\/span>.\u00a0Ann Nutr Metab<\/em><\/span>.\u00a02015<\/span>;66(Suppl. 2)<\/span>:14<\/span>\u201320<\/span>.\u00a0DOI<\/span>:\u00a010.1159\/000371628<\/span>.<\/p>\r\n

108.<\/span>\u00a0Ni<\/span>\u00a0L-F<\/span><\/span>,\u00a0Han<\/span>\u00a0Y<\/span><\/span>,\u00a0Wang<\/span>\u00a0S-S<\/span><\/span>,\u00a0et al<\/span>.\u00a0Association of placental PPAR\u03b1\/\u03b3 and miR-27b expression with macrosomia in healthy pregnancy<\/span>.\u00a0Pediatr Res<\/em><\/span>.\u00a02023<\/span>;93<\/span>:267<\/span>\u201373<\/span>.\u00a0DOI<\/span>:\u00a010.1038\/s41390-022-02072-1<\/span>.<\/p>\r\n

109.<\/span>\u00a0Lu<\/span>\u00a0Y<\/span><\/span>,\u00a0Tang<\/span>\u00a0Q<\/span><\/span>,\u00a0Yang<\/span>\u00a0S<\/span><\/span>,\u00a0et al<\/span>.\u00a0Downregulation of lncRNA\u00a0USP2\u2011AS1<\/em>\u00a0in the placentas of pregnant women with non\u2011diabetic fetal macrosomia promotes trophoblast cell proliferation<\/span>.\u00a0Mol Med Rep. <\/em><\/span>2022<\/span>;26<\/span>:250. <\/span>DOI<\/span>:\u00a010.3892\/mmr.2022.12766<\/span>.<\/p>\r\n

110.<\/span>\u00a0Guiyu<\/span>\u00a0S<\/span><\/span>,\u00a0Quan<\/span>\u00a0N<\/span><\/span>,\u00a0Ruochen<\/span>\u00a0W<\/span><\/span>,\u00a0et al<\/span>.\u00a0LncRNA-SNX17 promotes HTR-8\/SVneo proliferation and invasion through miR-517a\/IGF-1 in the placenta of diabetic macrosomia<\/span>.\u00a0Reprod Sci<\/em><\/span>.\u00a02022<\/span>;29<\/span>:596<\/span>\u2013605<\/span>.\u00a0DOI<\/span>:\u00a010.1007\/s43032-021-00687-z<\/span>.<\/p>\r\n

111.<\/span>\u00a0Shang<\/span>\u00a0M<\/span><\/span>,\u00a0Lin<\/span>\u00a0L<\/span><\/span>.\u00a0IADPSG criteria for diagnosing gestational diabetes mellitus and predicting adverse pregnancy outcomes<\/span>.\u00a0J Perinatol<\/em><\/span>.\u00a02014<\/span>;34<\/span>:100<\/span>\u20134<\/span>.\u00a0DOI<\/span>:\u00a010.1038\/jp.2013.143<\/span>.<\/p>\r\n

112.<\/span>\u00a0Shang<\/span>\u00a0M<\/span><\/span>,\u00a0Wen<\/span>\u00a0Z<\/span><\/span>.\u00a0Increased placental IGF-1\/mTOR activity in macrosomia born to women with gestational diabetes<\/span>.\u00a0Diabetes Res Clin Pract<\/em><\/span>.\u00a02018<\/span>;146<\/span>:211<\/span>\u20139<\/span>.\u00a0DOI<\/span>:\u00a010.1016\/j.diabres.2018.10.017<\/span>.<\/p>\r\n

113.<\/span>\u00a0Niang-Ndiaye<\/span>\u00a0M<\/span><\/span>,\u00a0Camara<\/span>\u00a0T<\/span><\/span>,\u00a0Cissokho<\/span>\u00a0S<\/span><\/span>,\u00a0et al<\/span>.\u00a0[Value of PCR in the diagnosis of tuberculosis in samples negative by direct examination in HIV+ and HIV patients]. [Article in French]<\/span>.\u00a0Dakar Med<\/em><\/span>.\u00a01993<\/span>;38<\/span>:165<\/span>\u20137<\/span>.<\/p>\r\n

114.<\/span>\u00a0Shankar<\/span>\u00a0R<\/span><\/span>,\u00a0Ramarajan<\/span>\u00a0A<\/span><\/span>,\u00a0Rani<\/span>\u00a0S<\/span><\/span>,\u00a0Seshiah<\/span>\u00a0V<\/span><\/span>.\u00a0Anthropometric and skin fold thickness measurements of newborns of gestational glucose intolerant mothers: Does it indicate disproportionate fetal growth?<\/span>\u00a0J Obstet Gynaecol India. <\/em><\/span>2020<\/span>;70<\/span>:471<\/span>\u20138. <\/span>DOI<\/span>:\u00a010.1007\/s13224-020-01340-6<\/span>.<\/p>\r\n

115.<\/span>\u00a0Mitanchez<\/span>\u00a0D<\/span><\/span>,\u00a0Jacqueminet<\/span>\u00a0S<\/span><\/span>,\u00a0Nizard<\/span>\u00a0J<\/span><\/span>,\u00a0et al<\/span>.\u00a0Effect of maternal obesity on birthweight and neonatal fat mass: A prospective clinical trial<\/span>.\u00a0PLoS One<\/em><\/span>.\u00a02017<\/span>;12<\/span>:e0181307<\/span>.\u00a0DOI<\/span>:\u00a010.1371\/journal.pone.0181307<\/span>.<\/p>\r\n

116.<\/span>\u00a0Ozler<\/span>\u00a0S<\/span><\/span>,\u00a0Kozanhan<\/span>\u00a0B<\/span><\/span>,\u00a0Bardak<\/span>\u00a0O<\/span><\/span>,\u00a0Ar\u0131kan<\/span>\u00a0MN<\/span><\/span>.\u00a0Are body roundness index and a body shape index in the first trimester related to foetal macrosomia?<\/span>.\u00a0J Obstet Gynaecol<\/em><\/span>.\u00a02022<\/span>;42<\/span>:396<\/span>\u2013402<\/span>.\u00a0DOI<\/span>:\u00a010.1080\/01443615.2021.1907565<\/span>.<\/p>\r\n

117.<\/span>\u00a0Bo<\/span>\u00a0S<\/span><\/span>,\u00a0Valpreda<\/span>\u00a0S<\/span><\/span>,\u00a0Menato<\/span>\u00a0G<\/span><\/span>,\u00a0et al<\/span>.\u00a0Should we consider gestational diabetes a vascular risk factor? <\/span>Atherosclerosis. <\/em><\/span>2007<\/span>;194<\/span>:e72<\/span>\u20139. <\/span>DOI<\/span>:\u00a010.1016\/j.atherosclerosis.2006.09.017<\/span>.<\/p>\r\n

118.<\/span>\u00a0Lauenborg<\/span>\u00a0J<\/span><\/span>,\u00a0Hansen<\/span>\u00a0T<\/span><\/span>,\u00a0Jensen<\/span>\u00a0DM<\/span><\/span>,\u00a0et al<\/span>.\u00a0Increasing incidence of diabetes after gestational diabetes: A long-term follow-up in a Danish population<\/span>.\u00a0Diabetes Care<\/em><\/span>.\u00a02004<\/span>;27<\/span>:1194<\/span>\u20139<\/span>.\u00a0DOI<\/span>:\u00a010.2337\/diacare.27.5.1194<\/span>.<\/p>\r\n

119.<\/span>\u00a0Barbour<\/span>\u00a0LA<\/span><\/span>,\u00a0Shao<\/span>\u00a0J<\/span><\/span>,\u00a0Qiao<\/span>\u00a0L<\/span><\/span>,\u00a0et al<\/span>.\u00a0Human placental growth hormone increases expression of the P85 regulatory unit of phosphatidylinositol 3-kinase and triggers severe insulin resistance in skeletal muscle. <\/span>Endocrinology. <\/em><\/span>2004<\/span>;145<\/span>:1144<\/span>\u201350. <\/span>DOI<\/span>:\u00a010.1210\/en.2003-1297<\/span>.<\/p>\r\n

120.<\/span>\u00a0Liao<\/span>\u00a0S<\/span><\/span>,\u00a0Vickers<\/span>\u00a0MH<\/span><\/span>,\u00a0Evans<\/span>\u00a0A<\/span><\/span>,\u00a0et al<\/span>.\u00a0Comparison of pulsatile vs. continuous administration of human placental growth hormone in female C57BL\/6J mice<\/span>.\u00a0Endocrine<\/em><\/span>.\u00a02016<\/span>;54<\/span>:169<\/span>\u201381<\/span>.\u00a0DOI<\/span>:\u00a010.1007\/s12020-016-1060-0<\/span>.<\/p>","wpcf-article_received_date":"20230628","wpcf-article_accepted_date":"20230801","wpcf-article_published_online":"20240319","wpcf-podcast":"","wpcf-ogg":"","wpcf-article_end_page":"","wpcf-article_start_page":"","wpcf-acknowledgements":"","wpcf-errata_pdf":"","wpcf-article_flipper_image":"","wpcf-corrected_online":null,"wpcf-supplementary_information":"","wpcf-article_highlight_pdf":"","data_availability":"Data sharing is not applicable to this article as no datasets were generated or analyzed during the writing of this article.","digital_features":""},"_links":{"self":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts\/77182"}],"collection":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/users\/142327"}],"replies":[{"embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/comments?post=77182"}],"version-history":[{"count":22,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts\/77182\/revisions"}],"predecessor-version":[{"id":93032,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/posts\/77182\/revisions\/93032"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media\/31137"}],"wp:attachment":[{"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/media?parent=77182"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/categories?post=77182"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/touchendocrinology.com\/wp-json\/wp\/v2\/tags?post=77182"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}